toolName,toolType,_pmid,_doi,_publicationTitle,_year,_confidence,_usageType,nf_specific,completeness_score,priority,strainNomenclature,animalModelGeneticDisorder,animalModelOfManifestation,targetAntigen,hostOrganism,clonality,organ,cellLineGeneticDisorder,cellLineManifestation,cellLineCategory,insertName,vectorType,vectorBackbone,promoter,softwareName,softwareType,softwareVersion,sourceRepository,modelType,derivationSource,cellTypes,organoidType,modelSystemType,patientDiagnosis,hostStrain,tumorType,assessmentName,assessmentType,targetPopulation,diseaseSpecific,numberOfItems,_context,filter_reason
Matrigel spheroids,advanced_cellular_models,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,cell line,,,,,,,,,,,,NF1-deficient MUT-45 spheroids grow larger than NF1-EV spheroids when grown in Matrigel,Publication title lacks 3D/organoid/spheroid terminology
primary cultures derived from plexiform neurofibromas,advanced_cellular_models,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,other,patient tissue,"Schwann cells, fibroblasts",,,,,,,,,,,Primary cultures containing tumor and nontumor stromal cells were utilized in a novel strategy to test drug responses...four primary cultures derived from plexiform neurofibromas,Publication title lacks 3D/organoid/spheroid terminology
oviductal organoids,advanced_cellular_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,organoid,primary cell,oviductal epithelial cells,oviductal organoid,,,,,,,,,,establish organoid-based tumor progression models of HG-SOC from murine oviductal and OSE tissues,Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
OSE organoids,advanced_cellular_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,organoid,primary cell,ovarian surface epithelium,OSE organoid,,,,,,,,,,establish organoid-based tumor progression models of HG-SOC from murine oviductal and OSE tissues,Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
neurofibromaspheres,advanced_cellular_models,PMID:41022755 | PMID:26904939,10.1038/s41467-025-63619-4 | 10.1016/j.celrep.2016.01.074,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,iPSC,"Schwann cells, fibroblasts",,,,,,,,,,,"neurofibromaspheres were obtained by 3D culture of differentiating pNF iPSC-derived Schwann cells (SC) with pNF patient-derived NF1 fibroblasts | For mouse or human neurofibroma spheres, we chopped tissue into 1–3 mm³ pieces",Publication title lacks 3D/organoid/spheroid terminology
S462 spheres,advanced_cellular_models,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,cell line,MPNST cells,,,,,,,,,,,The culture of S462 spheres followed the protocol in [22],Publication title lacks 3D/organoid/spheroid terminology
optic glioma neurospheres,advanced_cellular_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,Neural stem cells,neurosphere,,,,,,,,,,"Optic chiasm was microdissected from 3-month-old Nf1 flox/flox, Nf1 +/− and Nf1 +/− GFAP CKO mice to generate primary optic nerve neurospheres",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
hiMGL cells,advanced_cellular_models,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,other,iPSC,Microglia-like cells,,,,,,,,,,,"hiMGL cells were generated from hiPSCs as previously described (McQuade et al., 2018) with minor modifications",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
3D tumor spheroid model,advanced_cellular_models,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,cell line,"sNF96.2-luciferase cells, primary tumor cells",,,,,,,,,,,Their anti-tumor efficacy was further evaluated using a 3D tumor spheroid model,Publication title lacks 3D/organoid/spheroid terminology
neurosphere cultures,advanced_cellular_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,neural stem/progenitor cells,,,,,,,,,,,"We established and maintained neurosphere cultures as described (31) with some modifications. Briefly, we dissected out the lateral walls of the lateral ventricle or whole brain tumor",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
embryonic mouse spheres,advanced_cellular_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,DRG cells,,,,,,,,,,,"Embryonic mouse spheres, dissociated from E12.5 DRG with 0.25% Trypsin 20 min. at 37°C",Publication title lacks 3D/organoid/spheroid terminology
neurofibromasphere model,advanced_cellular_models,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,iPSC,"Schwann cells, fibroblasts",,,,,,,,,,,induced pluripotent stem cell-derived 3D neurofibromasphere model,Publication title lacks 3D/organoid/spheroid terminology
3D microtissues,advanced_cellular_models,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,patient tissue,,,,,,,,,,,,Selected PDX were harvested for assembly into 3D microtissues,Publication title lacks 3D/organoid/spheroid terminology
BioCoat Matrigel invasion chambers (Becton Dickinson),advanced_cellular_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,other,other,,,,,,,,,,,,In vitro invasion of MM cell from Nf2+/−;p16/p19+/− wild-type mice were measured using 24-well BioCoat Matrigel invasion chambers (Becton Dickinson),Publication title lacks 3D/organoid/spheroid terminology
NF1 patient-derived induced pluripotent stem cells (iPSCs),advanced_cellular_models,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,other,patient tissue,pluripotent stem cells,,,,,,,,,,,the availability of NF1 patient-derived induced pluripotent stem cells (iPSCs) provides new opportunities to define the critical factors,Publication title lacks 3D/organoid/spheroid terminology
C57BL/6J,animal_models,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.9,Experimental Usage,True,1.00,High,C57BL/6J,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C57BL/6J mice in which one allele of the NF1 gene has been targeted were generated as described elsewhere,Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
Nf1 P1,animal_models,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,1.00,High,Nf1 P1,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 P1 mutation was backcrossed six generations into the w CS10 genetic background and w CS10 flies were used as controls.,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Mut3,animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,Experimental Usage,True,1.00,High,Mut3,Neurofibromatosis type 1,astrocytomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To generate Mut3 to Mut6 mice (see Fig. 1A for genetic configurations), we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
Mut4,animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,Experimental Usage,True,1.00,High,Mut4,Neurofibromatosis type 1,astrocytomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To generate Mut3 to Mut6 mice (see Fig. 1A for genetic configurations), we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
"Mx1-Cre, Nf1 flox/flox",animal_models,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.95,Experimental Usage,True,1.00,High,"Mx1-Cre, Nf1 flox/flox",Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mx1-Cre, Nf1 flox/flox mice (129SV × C57BL/6 J) were generated and somatic Nf1 inactivation was induced as described elsewhere","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
Nf1flox/null; GFAP-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/null; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice",Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Nf1flox/R681*; GFAP-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/R681*; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice",Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Nf1flox/null; Ptenflox/wt; GFAP-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/null; Ptenflox/wt; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice",Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Nf1flox/null; Olig2-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/null; Olig2-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice",Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
cis Nf1+/−;P53+/−,animal_models,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,cis Nf1+/−;P53+/−,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cisMPNST cells were derived from spontaneous MPNSTs arising in cis Nf1+/−;P53+/− mice,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f,animal_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Eed f/f mice (67, 68) were bred with PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f mice",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
NPcis (Stock #008191),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,True,1.00,High,NPcis (Stock #008191),Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Publication title lacks NF-specific terms: A genetic mouse model with postnatal
Nf1 (#017640),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,True,1.00,High,Nf1 (#017640),Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Publication title lacks NF-specific terms: A genetic mouse model with postnatal
P-cadherin,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-cadherin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were P-cadherin (R&D Systems, AF761), DCT (PEP8h; gift from Dr. Vincent Hearing)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
DCT,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.67,Low,,,,DCT,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"DCT (PEP8h; gift from Dr. Vincent Hearing, National Institutes of Health)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
K14,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.67,Low,,,,K14,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
LacZ,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.33,Low,,,,LacZ,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
GFP/YFP,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.33,Low,,,,GFP/YFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
KIT,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,True,0.33,Medium,,,,KIT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074). For immunofluorescent staining",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
Thy1.1,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,Thy1.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,Thy1.1-APC (ganglion cell marker),Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Cmyc,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,Cmyc,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Cmyc-FITC, Oct4-APC (stemness markers)",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Oct4,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,Oct4,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Cmyc-FITC, Oct4-APC (stemness markers)",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
STEM121,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,STEM121,,,,,,,,,,,,,,,,,,,,,,,,,,,,STEM121-FITC (human cell marker),Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Vinculin,antibodies,PMID:36730269 | PMID:31836666 | PMID:38502231 | PMID:37164978 | PMID:38481529 | PMID:38127282 | PMID:33658640 | PMID:36689660,10.1371/journal.pone.0277305 | 10.1074/jbc.RA119.010934 | 10.1172/JCI176748 | 10.1038/s41467-023-38432-6 | 10.3389/fcell.2024.1359561 | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41416-021-01270-8 | 10.1073/pnas.2208960120,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.95,Experimental Usage,False,0.33,Low,,,,Vinculin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Vinculin (Catalogue # 4650) | vinculin (Cell Signaling 19301) | vinculin (4650S, Cell Signaling Technology) | Vinculin(1:30000, Cat #V9264, Sigma Aldrich) | anti-vinculin (abcam, ab129002, 1/1000) was used to verify equal protein loading | Vinculin (ab219649, 1:1000 dilution, Abcam) | Vinculin (mouse, V284, Sigma, St. Louis, MO, USA) | GST and Vinculin (Bethyl Laboratories)",Generic loading-control antibody: vinculin
β-actin,antibodies,PMID:33078583 | PMID:38201517 | PMID:41022755 | PMID:18451155 | PMID:32438526 | PMID:32457840 | PMID:24509877 | PMID:34040258 | PMID:33436083 | PMID:34011935 | PMID:41036607 | PMID:21072183 | PMID:26904939 | PMID:33934112 | PMID:20049725 | PMID:24371224 | PMID:23328114 | PMID:30274821 | PMID:32419643,10.1002/jcsm.12632 | 10.3390/cancers16010089 | 10.1038/s41467-025-63619-4 | 10.1158/0008-5472.CAN-07-6867 | 10.1002/lary.28671 | 10.3389/fonc.2020.00687 | 10.1038/onc.2013.506 | 10.1038/s41586-021-03580-6 | 10.1186/s13072-020-00380-6 | 10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-24-1053 | 10.1371/journal.pone.0013791 | 10.1016/j.celrep.2016.01.074 | 10.1038/s41419-021-03716-6 | 10.1002/emmm.200900027 | 10.1158/0008-5472.CAN-13-2062 | 10.18632/oncotarget.793 | 10.1016/j.ebiom.2018.09.042 | 10.1177/1533033820919759,"Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.",,0.95,Experimental Usage,False,0.67,Low,,,,β-actin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-β-actin (Cell Signaling Technology 58169) | β-actin was detected with a 1:25,000 dilution of murine monoclonal antibody to β-actin (Sigma, St. Louis, MI, USA, product #A5441). | The anti-βActin (C-11, SC-1615HRP) HRP antibody was purchased from Santa Cruz Biotechnology | Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma) | The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316) | Primary antibodies used in western blot analysis were: mouse anti-β-actin, mouse anti-α-tubulin, and mouse anti-α-smooth muscle actin (α-SMA), all from Sigma-Aldrich | p473AKT, AKT, and β-ACTIN (Cell Signaling) as a loading control | rabbit anti-β-actin, 1:10,000, Cell Signaling 4970 lot 15 | β-Actin (Cell Signaling #3700) | Antibodies used in western blotting targeting β-actin (#13E5) | β-Actin was probed as a loading control using β-actin (13E5) rabbit mAb #4970 (RRID: AB_2223172) | The antibodies used in this study include... β-actin (Sigma) | Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA) | mouse monoclonal anti-β actin was from Santa Cruz (Cat. #sc-47778) | then re-probed with anti-β-actin (Cell Signaling Technology, Inc. #4967) as a loading control | and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz | β-actin (Sigma) | The β-actin antibody (# AA128, Beyotime) was used to ensure equal loading of total protein | The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",Generic loading-control antibody: β-actin
GAPDH,antibodies,PMID:38201517 | PMID:33442015 | PMID:32383545 | PMID:23175151 | PMID:37446790 | PMID:32461556 | PMID:33273014 | PMID:38502231 | PMID:39129390 | PMID:28126595 | PMID:23535903 | PMID:24681606 | PMID:34065204 | PMID:23685747 | PMID:26219339 | PMID:38714355 | PMID:36148553 | PMID:38203448 | PMID:24824755 | PMID:29847659 | PMID:29670214 | PMID:25043298 | PMID:36241865,10.3390/cancers16010089 | 10.1038/s41591-020-01193-6 | 10.15252/embr.201949117 | 10.1038/bjc.2012.518 | 10.3390/molecules28135128 | 10.1038/s41467-020-16432-0 | 10.1074/jbc.RA120.014960 | 10.1172/JCI176748 | 10.1002/1878-0261.13704 | 10.1016/j.ebiom.2017.01.020 | 10.1158/2159-8290.CD-13-0081 | 10.18632/oncotarget.1609 | 10.3390/ijms22105367 | 10.1038/ng.2641 | 10.18632/oncotarget.4858 | 10.1158/1535-7163.MCT-23-0510 | 10.1093/brain/awac342 | 10.3390/ijms25010277 | 10.1371/journal.pone.0096733 | 10.1167/iovs.17-22588 | 10.1038/s41598-018-24310-5 | 10.1038/onc.2014.185 | 10.1038/s12276-022-00850-9,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Restoring functional neurofibromin by protein transduction. | Oncogenic role of Merlin/NF2 in glioblastoma. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.",,0.95,Experimental Usage,False,1.00,Medium,,,,GAPDH,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH was detected with a 1:1000 dilution of rabbit polyclonal antibody to GAPDH (Cell Signaling, Boston, MA, USA, product #2118). | pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology) | anti‐GAPDH (#2118, Cell Signaling), ATP5A (ab14748, Abcam) | GAPDH mouse mAb (6C5) (dilution 1 : 5000; incubation 1 h at room temperature; Advanced Immunochemical Inc.) | Antibodies against GAPDH (cat. no. 5174S)...were obtained from Cell Signaling Technology | GAPDH (LN2100751, 1:1000, Labned) | Other antibodies included... and GAPDH (EMD Millipore) | GAPDH (SC-32233, Santa Cruz Biotechnology) | GAPDH (rabbit, Proteintech 10 494‐1‐AP, San Diego, CA USA, 1 : 15 000) | PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore | The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling) | GAPDH (Cell Signaling 1:2000) | human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam | probed with antibodies against FOXR2 (SIGMA) and GAPDH (Cell Signaling Tech.) | GAPDH (EMD Millipore) | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology | GAPDH (1:5000; AB2302; Merck) | The primary antibodies used in the study include anti-GAPDH (Proteintech Group Inc., Rosemont, IL, USA) | GAPDH, BCL-2 and PUMA (Cell Signaling, Danvers, MA) | and anti-GAPDH (Novus, Littleton, CO, USA) | anti-GAPDH; Santa Cruz Biotechnology Inc.; 1:3000 | Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling) | Anti-GAPDH antibody primary WB CST",Generic loading-control antibody: gapdh
HMGA2,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.33,Low,,,,HMGA2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
CK19,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.33,Low,,,,CK19,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
α-tubulin,antibodies,PMID:19191334 | PMID:32642733 | PMID:38203448 | PMID:21216928,10.1002/glia.20845 | 10.1093/noajnl/vdz061 | 10.3390/ijms25010277 | 10.1158/1535-7163.MCT-10-0654,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.9,Experimental Usage,False,0.33,Low,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"α-tubulin (Sigma, St. Louis, MO) was employed for normalization and densitometric analysis | anti-α-tubulin (Sigma-Aldrich) | anti-α-tubulin-Alexa488 antibody (Life Technologies) | anti-α-tubulin (Proteintech Group Inc., Rosemont, IL, USA) | using α-tubulin (Sigma, St. Louis MO), β-actin or non-phospho-STAT3, AKT, S6, and 4EBP1 antibodies for normalization",Generic loading-control antibody: α-tubulin
DDK tag,antibodies,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,0.33,Low,,,,DDK tag,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The expression of the DDK-tagged transcript was validated by Western blot using anti-DDK antibodies,Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
YAP1,antibodies,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,Experimental Usage,True,0.33,Medium,,,,YAP1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody specific for YAP1 was from Cell Signaling Inc.,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
Pten,antibodies,PMID:32699356 | PMID:18451155,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.67,Medium,,,,Pten,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-Pten (9559S, 1:1000, Cell Signaling) | glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers), nestin (BD Bioscience) | Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
PAX8,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,PAX8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PAX8 Proteintech, 10336-1-AP 1:2000 Overnight, RT Citrate buffer, pH 6.0",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Ac-alpha-Tubulin,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,Ac-alpha-Tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ac-alpha-Tubulin Santa Cruz, sc-23950 1:2000 Overnight, RT Citrate buffer, pH 6.0",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
γH2A.X,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,γH2A.X,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-γH2A.X primary antibody (1:500, Millipore, clone JBW301)",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
glutamine synthetase,antibodies,PMID:34415582 | PMID:32396062,10.1002/glia.24075 | 10.7554/eLife.55137,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.95,Experimental Usage,False,1.00,Medium,,,,glutamine synthetase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-glutamine synthetase (GS), Sigma-Aldrich, Cat. #MAB302 (1/500) | Antibody anti-glutamine synthetase (GS), mouse monoclonal Sigma-Aldrich Cat. # MAB302 RRID: AB_2110656",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
IL6 receptor,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,False,0.67,Low,,,,IL6 receptor,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell.,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
TNFα,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,False,0.33,Low,,,,TNFα,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-mTNFα antibody (R023) was purchased from Sino Biological,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
IL3,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,False,0.67,Low,,,,IL3,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-mIL3 antibody (MP2–8F8) was purchased from BD Biosciences.,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
B-Actin,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,0.33,Low,,,,B-Actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies for B-Actin(1:1000, Cat #8457S, Cell Signaling Technologies)",Generic loading-control antibody: b-actin
activated β-catenin,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.33,Low,,,,activated β-catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
GSK3B,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.33,Low,,,,GSK3B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
AXIN1,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.33,Low,,,,AXIN1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
CCND1,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.67,Low,,,,CCND1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
HK2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,0.67,Low,,,,HK2,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"primary goat polyclonal anti‐HK2 (sc‐6521, Santa Cruz) and rabbit monoclonal anti‐MPP2 | Primary antibodies (rabbit monoclonal anti‐HK2, H.738.7, Thermo Scientific; mouse monoclonal anti‐TOM20",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
MPP2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,1.00,Medium,,,,MPP2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit monoclonal anti‐MPP2 (ab92536, Abcam) antibodies",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
ATP5A,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,0.33,Low,,,,ATP5A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ATP5A (ab14748, Abcam), anti‐UQCRC2 (ab14745, Abcam)",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
UQCRC2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,0.33,Low,,,,UQCRC2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐UQCRC2 (ab14745, Abcam), rabbit monoclonal anti‐MMP2 (ab92536, Abcam)",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
MMP9,antibodies,PMID:32383545 | PMID:23175151,10.15252/embr.201949117 | 10.1038/bjc.2012.518,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,False,1.00,Medium,,,,MMP9,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit monoclonal anti‐MMP9 (ab137867, Abcam) rabbit polyclonal, and TOM20 | rabbit monoclonal (EP1254) MMP9 (dilution 1 : 1000; incubation overnight at 4 °C, Abcam",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Mi
TOM20,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,0.33,Low,,,,TOM20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TOM20 (sc‐11415, Santa Cruz) antibodies | mouse monoclonal anti‐TOM20, sc‐17764, Santa Cruz) were diluted 1:150",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
Beta-Actin,antibodies,PMID:36730269 | PMID:41564118 | PMID:38481529,10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3389/fcell.2024.1359561,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.33,Low,,,,Beta-Actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Beta-Actin (Catalogue # NB600-501) was purchased from Novus | beta-actin (Cell Signaling cat# 3700 1:10000) | Anti-beta-Actin antibody (Santa Cruz Biotechnologies, sc4778, 1/10,000) was used to verify equal protein loading",Generic loading-control antibody: beta-actin
TRAP1,antibodies,PMID:35614131 | PMID:33934112,10.1038/s41418-022-01020-0 | 10.1038/s41419-021-03716-6,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,TRAP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-human TRAP1 (sc-73604) | Mouse monoclonal anti-rodent TRAP1 was from Becton Dickinson (Cat. #612344) | mouse monoclonal anti-human TRAP1 was from Santa Cruz (Cat. #sc-73604),Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation. | 
ATP50/OSCP,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,ATP50/OSCP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti ATP50/OSCP (ab110276) antibodies,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
ATPB,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,ATPB,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-ATPB (ab14730),Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
SDHA,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,SDHA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti SDHA (sc-166947),Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
Cyclophilin,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,Cyclophilin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-Cyclophilin (ab110324) antibodies,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
MMP2,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,False,1.00,Medium,,,,MMP2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal (CA-4001) matrix metalloproteinase (MMP)2...dilution 1 : 1000; incubation overnight at 4 °C, Abcam",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
MMP3,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,Experimental Usage,False,0.33,Low,,,,MMP3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"MMP3 (dilution 1 : 50; incubation overnight at 4 °C, Santa Cruz Biotechnology, Inc.)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
TRA-1-60,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,False,0.33,Low,,,,TRA-1-60,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
SSEA-4,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,False,0.33,Low,,,,SSEA-4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
phospho-Akt,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
p-4EBP,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.33,Low,,,,p-4EBP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-4EBP (Cell Signaling 1:500),Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
p-RB1-S807/811,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.95,Experimental Usage,True,0.33,Medium,,,,p-RB1-S807/811,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
RB1,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,True,0.33,Medium,,,,RB1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
nc82,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,False,0.67,Low,,,,nc82,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The following antibodies were used: rabbit anti-GFP (1:1000, Invitrogen), mouse anti-nc82 (1:50, DSHB)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Ki67 antigen,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,Ki67 antigen,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
glial fibrillary acidic protein,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,glial fibrillary acidic protein,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
phosphorylated Akt,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,phosphorylated Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
BrdUrd,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,BrdUrd,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO), Olig2 (Chemicon)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
doublecortin,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,doublecortin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Olig2 (Chemicon), or doublecortin (Santa Cruz). We used microwave antigen retrieval for all antibodies, except for doublecortin antibody",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
Histone H3,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,Histone H3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology",Generic loading-control antibody: histone h3
"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",antibodies,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.9,Experimental Usage,True,0.33,Medium,,,,"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",,,,,,,,,,,,,,,,,,,,,,,,,,,,"Total BM cells were labeled with biotin-conjugated α-Lin Abs, consisting of α-CD3e, α-CD11b, α-CD45R/B220, α-Ly6G/Ly6C, and α-TER-119 Abs","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
Ago2,antibodies,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,False,0.33,Low,,,,Ago2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Bound RNA and protein of interest is immunoprecipitated using the Ago2 antibody (Cell Signaling Technology, Beverly, MA, USA) at a dilution of 1:50",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
citrate synthetase,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,citrate synthetase,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-citrate synthetase was from Abcam (Cat. #ab96600),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
Etv5,antibodies,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,Etv5,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Rabbit anti-Etv5 antibody (Novus Biologicals) was diluted at 1:100 for immunohistochemistry,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Ly6G,antibodies,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.9,Experimental Usage,False,0.33,Low,,,,Ly6G,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Depletion of neutrophils via anti-Ly6G antibody or bone marrow suppression using hydroxyurea significantly improved tumor clearance.,Publication title lacks NF-specific terms: Neutrophil depletion enhanced the
pSmad3,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,pSmad3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-pSmad3, rabbit monoclonal Abcam Cat. # ab52903 RRID: AB_882596 1/200 dilution",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
Zpr-1,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,Zpr-1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody Zpr-1, mouse monoclonal Zebrafish International Resource Center Cat. # zpr-1 RRID: AB_10013803",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
Zn-5,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,Zn-5,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody Zn-5, mouse monoclonal Zebrafish International Resource Center Cat. # zn-5 RRID: AB_10013770",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
HuC/D,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,HuC/D,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-HuC/D, rabbit polyclonal Abcam Cat. # ab210554 RRID: AB_210554 1/500 dilution",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
PKC β1,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,PKC β1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-PKC β1, mouse monoclonal Santa Cruz Biotechnology Cat. # SC-8049 RRID: AB_628143",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
β-tubulin III,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.33,Low,,,,β-tubulin III,,,,,,,,,,,,,,,,,,,,,,,,,,,,β-tubulin III-FITC (neurofibroma presence),Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
FAP,antibodies,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,False,0.67,Low,,,,FAP,Unknown,Recombinant,,,,,,,,,,,,,,,,,,,,,,,,,,"A recombinant anti-FAP antibody (clone ab207178, Abcam, Cambridge, UK) was applied at a dilution of 1:250",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
EGFP,antibodies,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,EGFP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"EGFP (Thermo Fisher Scientific; 11575712, clone F56-6A1.2.3)",Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
BIM,antibodies,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,0.67,Low,,,,BIM,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies: anti-human C-terminal BIM (goat, Bio-RAD, Hercules, CA, USA, AHP2074; 1:1000) | anti-human N-terminal BIM (C34C5) (rabbit, Cell Signaling, #2933; 1:1000)",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
b-tubulin,antibodies,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,1.00,Medium,,,,b-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-b-tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1:10,000)",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
nitrated Hsp90,antibodies,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.95,Experimental Usage,False,0.33,Low,,,,nitrated Hsp90,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,in-house developed antibodies specific for Hsp90 nitrated at Tyr 33 or Tyr 56 (dilution 1:200),Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
human retinal ganglion cells (hRGC),cell_lines,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Eye,,,,,,,,,,,,,,,,,,,,,,,,,"Human retinal ganglion cells (hRGC), gifted from Dr. Donald Zack laboratory, were described in previous studies, being Brn3b-TdTomato positive",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Primary Schwannoma Cells,cell_lines,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Primary cells were isolated using the methods described by Rosenbaum et al. Schwannoma tissues were dissected,Generic cell line name: Primary Schwannoma Cells
ipNF 95.11b,cell_lines,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized NF1 patient derived Schwann cell (NF SC, NF-/-) line, ipNF 95.11b and Wild type Schwann cell (WT SC, NF+/+) line, ipn 02.8 were utilized for all experiments",Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
ipn 02.8,cell_lines,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Wild type Schwann cell (WT SC, NF+/+) line, ipn 02.8 were utilized for all experiments. The cells were extracted from human patients diagnosed with Plexiform Neurofibroma",Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
p53−/− mouse embryonic liver progenitor cells,cell_lines,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Liver,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,We performed a genome-wide CRISPR/Cas9-based knockout screen of P53-null mouse embryonic liver progenitor cells that overexpressed MYC,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
293fs cells,cell_lines,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,293fs cells were used to package lentivirus encoding individual sgRNA and Cas9,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
immortalized mouse Nf2 Schwann cells,cell_lines,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"immortalized mouse Nf2 Schwann cells, a gift from D. Lallemand (Centre National de la Recherche Scientifique, Institut Curie, Paris, France) (flox2/flox2)",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
CT26,cell_lines,PMID:30542164 | PMID:32383545,10.1038/s41586-018-0774-y | 10.15252/embr.201949117,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Colon,,Colon cancer,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The colon cancer cell line CT26 was injected subcutaneously into the right flank of 6–8-week-old female BALB/C mice | mouse colorectal carcinoma CT26 cells, mouse macrophage RAW 264.7 cells",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
U937,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human U937 cells were cultured in RPMI 1640 medium with 5% FBS and antibiotics, and were differentiated to M1 macrophage-like cells",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
Raji,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Burkitt's lymphoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Raji, a human Burkitt's lymphoma cell line, was purchased from Sigma.",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
Eμ-ALL,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,B-cell acute lymphoblastic leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The Eμ-ALL cell line was derived from a lymphoid malignancy in an Eμ-myc transgenic mouse and upon intravenous injection, can develop B-ALL in C57Bl/6 mice",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003),cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003) were purchased from Promab Biotechnologies,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
Epstein-Barr virus-transformed cell lines,cell_lines,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Blood,Neurofibromatosis Type 1,,Hybrid cell line,,,,,,,,,,,,,,,,,,,,,,"Hybrid cell lines harboring only the chromosome 17 with the deletion were established for patients 659, 619, 1106, DA-77 and ASB4-55 using Epstein-Barr virus-transformed cell lines",Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
TVZ NSCs,cell_lines,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Brain,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,TVZ NSCs were established from the third ventricle of 3-month-old Nf1 flox/flox and Nf1+/− mice,Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
iHSC1λ,cell_lines,PMID:23535903 | PMID:24681606,10.1158/2159-8290.CD-13-0081 | 10.18632/oncotarget.1609,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.",,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4 | Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4 R24C","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
iHSC2λ,cell_lines,PMID:23535903 | PMID:24681606,10.1158/2159-8290.CD-13-0081 | 10.18632/oncotarget.1609,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.",,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4 | Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4 R24C","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
MDA-MB-231 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human breast cancer MDA‐MB‐231 cells, human malignant peripheral nerve sheath tumor S462 cells",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
PN 04.4 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human plexiform neurofibroma PN 04.4 cells, mouse breast cancer 4T1 cells",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
4T1 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,mouse breast cancer 4T1 cells and mouse colorectal carcinoma CT26 cells,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
RAW 264.7 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mouse macrophage RAW 264.7 cells and, mouse myoblast C2C12 cells",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
COLO 741 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Colon,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,colorectal carcinoma COLO 741 cells and B‐CLL MEC1 cells were cultured in RPMI 1640 medium,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
MEC1 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,B‐CLL MEC1 cells were cultured in RPMI 1640 medium,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
U87 glioblastoma cells,cell_lines,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Experiments were performed on human U87 glioblastoma cells (ATCC),Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
sMPNST cells,cell_lines,PMID:35614131 | PMID:35393510,10.1038/s41418-022-01020-0 | 10.1038/s41418-022-00991-4,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mouse malignant peripheral nerve sheath tumor cells (sMPNST cells, kindly provided by Lu Q. Le, UTSW, Dallas, TX) | sMPNST cells were established from Nf1- and p53-deficient skin precursors (SKP)",Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation. | 
HT1080,cell_lines,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Connective tissue,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,compared with HT1080 WT for neurofibromin 1,Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
CTL BJFF.6 hiPSCs,cell_lines,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Skin,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,The original CTL BJFF.6 hiPSCs were generated from commercially available human foreskin fibroblasts,Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
human endothelial colony forming cells (ECFC),cell_lines,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Pooled human endothelial colony forming cells (ECFC, endothelial outgrowth cells) were purchased from the Angio BioCore at Indiana University",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
human microvascular endothelial cells (HMVEC),cell_lines,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Human microvascular endothelial cells (HMVEC) were purchased from Lonza (Allendale, NJ, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
293FT packaging cells,cell_lines,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"To generate lentiviral supernatant, 293FT packaging cells were plated onto tissue culture plates",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
Primary human Schwann cells (NHSC),cell_lines,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Primary human Schwann cells (NHSC) isolated from human spinal nerve were purchased from ScienCell Research Laboratories (Cat. #1700),Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
BY4743 background diploid yeast deletion strains,cell_lines,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Yeast,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Diploid yeast deletion strains used for growth analyses were of the BY4743 background (MATa/MATα, his3∆1/his3∆1, leu2∆0/leu2∆0...)","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
Y258 background haploid yeast MORF strain,cell_lines,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Yeast,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"The haploid yeast MORF (Movable ORF) strain for RAS1 overexpression was of the Y258 background (MATa, pep 4-3, his 4-580...)","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
MethoCult® M3434,cell_lines,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.8,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Colony forming unit granulocyte/macrophage (CFU-GM) progenitors were grown in MethoCult® (StemCell Technologies, Cat #03434)","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
M059J,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Primary normal human astrocytes (M059J) and 4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
U87,cell_lines,PMID:32419643 | PMID:33934112,10.1177/1533033820919759 | 10.1038/s41419-021-03716-6,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences | Experiments were performed on human U87 and U251 glioblastoma cells",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma. | HI
U118,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
A172,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
Wild-type and Nf1-/- primary astrocytes,cell_lines,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Brain,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Wild-type and Nf1-/- primary astrocytes were generated and maintained as previously described,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Sf21 insect cells,cell_lines,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Insect ovary,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Sf21 insect cells (Life Technologies, Carlsbad, CA, USA)...Sf21 cells were infected with saturating amounts",Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
E. coli DH10Multibac cells,cell_lines,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Bacterial,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,E. coli DH10Multibac cells containing the modified baculoviral genome,Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
Nf1−/− MEFs,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Embryonic tissue,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Mouse embryonic fibroblasts (MEFs) were derived from both wild type mice and syngenic neurofibromin 1 (Nf1)-knockout animals (Nf1+/+ and Nf1−/− MEFs, respectively)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
ipNF 04.4 cells,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human plexiform neurofibroma ipNF 04.4 cells were generated and provided by Dr. Margaret R. Wallace,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
GL261,cell_lines,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The mouse GL261 glioma cell line was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ), Germany, and was authenticated by DSMZ.",Publication title lacks NF-specific terms: Neutrophil depletion enhanced the
GL261-luc,cell_lines,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,GL261-luc cells were generated by infection of lentivirus carrying luciferase as described.,Publication title lacks NF-specific terms: Neutrophil depletion enhanced the
"M14 (ST88-14, RRID:CVCL_8916)",cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M14 (ST88-14, RRID:CVCL_8916) and M10 (MPNST1) were kind gifts provided by Jonathan A. Fletcher",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
M10 (MPNST1),cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M14 (ST88-14, RRID:CVCL_8916) and M10 (MPNST1) were kind gifts provided by Jonathan A. Fletcher",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
C6 cells,cell_lines,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,C6 rat glioma cells were injected into the optic nerve of Long-Evans rats and allowed to proliferate for 2 weeks,Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
MOLM-13,cell_lines,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Acute myeloid leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Early-passage MOLM-13 cells (DSMZ) were cultured in RPMI media,Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
293T lenti-X cells,cell_lines,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,293T lenti-X cells (Takara Bio) with TransIT-LT1,Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
BL21 (DE3) E.coli,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Bacteria,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Proteins were expressed in BL21 (DE3) E.coli and purified using Amersham HiTrap glutathione columns,Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
H929,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
U266B1,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
U2932,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
HT229,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Colon,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
HCC1937,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Except for MCF7, HT229, and HCC1937 (gifts from Dr. Bora Limb, MD Anderson Cancer Research Center, Houston, TX, USA), all cell lines were purchased from the American Type Culture Collection",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
"normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories)",cell_lines,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Low passage normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories, Carlsbad, CA, USA) were cultured on CellBIND dishes",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Mouse merlin-null schwannoma cells,cell_lines,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Mouse merlin-null schwannoma cells were generated in the laboratory of Dr. Cristina Fernandez-Valle by deleting the sequence coding for exon 2 in the Nf2 gene,Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Survey of Well-being of Young Children (SWYC),clinical_assessment_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Survey of Well-being of Young Children (SWYC),questionnaire,pediatric,No,,"...developmental delay assessed with the Survey of Well-being of Young Children...SWYC surveys conducted on the same days, which assess developmental milestones...","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Survey of Well-being of Young Children (SWYC)"
Centers for Disease Control (CDC) growth charts,clinical_assessment_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Centers for Disease Control (CDC) growth charts,scale,pediatric,No,,...We used the LMS method from Centers for Disease Control (CDC) growth charts on head circumference to compute Z scores...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Centers for Disease Control (CDC) growth charts"
National Institute of Health diagnostic criteria for NF1,clinical_assessment_tools,PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,National Institute of Health diagnostic criteria for NF1,structured interview,all ages,Yes,,"Participants were children aged 12–17 years meeting the National Institute of Health (National Institutes of Health Consensus Development Conference, 1988) diagnostic criteria for NF1.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: National Institute of Health diagnostic criteria for NF1"
P300 event-related potential,clinical_assessment_tools,PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,P300 event-related potential,biomarker assay,pediatric,No,,The aim of this study was to investigate P300 event-related potential (ERP) associated with WM in NF1...EEG was recorded during a WM nback task.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: P300 event-related potential"
WM nback task,clinical_assessment_tools,PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,WM nback task,performance test,pediatric,No,,EEG was recorded during a WM nback task. The NF1 group showed poorer performance on measures of WM as compared to the control group.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WM nback task"
P.L.E.A.S.E.® device,clinical_assessment_tools,PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,P.L.E.A.S.E.® device,other,adult,Yes,,"cNFs were laser-porated using the P.L.E.A.S.E.® device with the following user-defined settings: density of 10%, 5 pulses per pore, repetition rate of 300 Hz","Assessment name not in title and 'tool' not in title — likely generic usage, not development: P.L.E.A.S.E.® device"
Dermlite DL3,clinical_assessment_tools,PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Dermlite DL3,other,adult,Yes,,"visual and dermatoscopy observations (using the Dermlite DL3 [3Gen, San Jan Capistrano, CA, USA]) noting color and presence of necrosis","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Dermlite DL3"
NIH Consensus Development Conference NF1 diagnostic criteria,clinical_assessment_tools,PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH Consensus Development Conference NF1 diagnostic criteria,structured interview,all ages,Yes,,"patients with a clinical diagnosis of NF1 according to the NIH Consensus Development Conference NF1 diagnostic criteria (NIH, 1998)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NIH Consensus Development Conference NF1 diagnostic criteria"
Numerical Rating Scale-11,clinical_assessment_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Numerical Rating Scale-11,scale,all ages,Yes,1.0,The Numerical Rating Scale-11 is a self-report measure of pain intensity that was adapted to assess PN-related pain for NF1 clinical trials. Patients were asked to choose their most important tumor pain and rate it from 0 (no pain) to 10 (worst pain) in the past week.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Numerical Rating Scale-11"
Brief Pain Inventory Pain Interference subscale,clinical_assessment_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Pain Inventory Pain Interference subscale,scale,all ages,No,7.0,The Brief Pain Inventory Pain Interference subscale assesses the impact of pain on daily functioning in seven areas from 0 (does not interfere) to 10 (completely interfered) in the past week; it yields a mean total score.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brief Pain Inventory Pain Interference subscale"
Pediatric Quality of Life Inventory NF1 module,clinical_assessment_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Pediatric Quality of Life Inventory NF1 module,questionnaire,pediatric,Yes,16.0,The Pediatric Quality of Life Inventory NF1 module is a disease-specific health-related quality-of-life (QOL) measure assessing 16 domains. Responses on a five-point Likert scale are transformed to a scale of 0-100 (higher scores = better QOL); it produces mean domain and total scores.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pediatric Quality of Life Inventory NF1 module"
EQ-5D-5L,clinical_assessment_tools,PMID:32642740 | PMID:38811427,10.1093/noajnl/vdaa003 | 10.1186/s41687-024-00732-w,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. | Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EQ-5D-5L,questionnaire,adult,No,5.0,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference) | The EQ-5D-5L is a brief and generic health status measure that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression","Assessment name not in title and 'tool' not in title — likely generic usage, not development: EQ-5D-5L"
SF-36,clinical_assessment_tools,PMID:32642740 | PMID:38811427,10.1093/noajnl/vdaa003 | 10.1186/s41687-024-00732-w,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. | Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SF-36,questionnaire,adult,No,36.0,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference) | The 36-item Short Form Survey (SF-36) is a generic health-related QoL measure. It comprises eight domains of health: physical function, limitations because of physical problems","Assessment name not in title and 'tool' not in title — likely generic usage, not development: SF-36"
World Health Organization Quality of Life Brief Version (WHOQOL-BREF),clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),questionnaire,adult,No,26.0,The 2 primary outcomes were the physical health and psychological QOL domain scores of the World Health Organization Quality of Life Brief Version (WHOQOL-BREF),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: World Health Organization Quality of Life Brief Version (WHOQOL-BREF)"
Relaxation Response Resiliency Program for NF (3RP-NF),clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Relaxation Response Resiliency Program for NF (3RP-NF),structured interview,adult,Yes,,"mind-body skills training program, the Relaxation Response Resiliency Program for NF (3RP-NF)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Relaxation Response Resiliency Program for NF (3RP-NF)"
Health Enhancement Program for NF (HEP-NF),clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Health Enhancement Program for NF (HEP-NF),structured interview,adult,Yes,,health education program (Health Enhancement Program for NF; HEP-NF),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Health Enhancement Program for NF (HEP-NF)"
DPOAE,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,DPOAE,performance test,all ages,No,,We measure hearing function by DPOAE and ABR tests,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: DPOAE"
ABR,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ABR,performance test,all ages,No,,We measure hearing function by DPOAE and ABR tests,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: ABR"
hind-limb clasping test,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,hind-limb clasping test,performance test,all ages,No,,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests","Assessment name not in title and 'tool' not in title — likely generic usage, not development: hind-limb clasping test"
ledge test,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ledge test,performance test,all ages,No,,"In the CPA model, we found that the ledge test, which evaluates coordination, is the most sensitive test","Assessment name not in title and 'tool' not in title — likely generic usage, not development: ledge test"
rotarod assay,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,rotarod assay,performance test,all ages,No,,"Balance, motor strength, and coordination can be assayed by rotarod assay","Assessment name not in title and 'tool' not in title — likely generic usage, not development: rotarod assay"
Dermus SkinScanner,clinical_assessment_tools,PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Dermus SkinScanner,biomarker assay,all ages,Yes,,"measurements were performed at the Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, using a portable DG-HFUS device (Dermus SkinScanner, Dermus Ltd., Budapest, Hungary)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Dermus SkinScanner"
Wechsler Abbreviated Scale of Intelligence (WASI),clinical_assessment_tools,PMID:27081657 | PMID:28725547,10.1002/acn3.288 | 10.1016/j.nicl.2017.06.032,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I. | Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Abbreviated Scale of Intelligence (WASI),performance test,all ages,No,,"Full‐Scale IQ of at least 70, as determined by the Wechsler Abbreviated Scale of Intelligence (WASI 15 ) | Full-Scale IQ ≥ 70 (as determined by the Wechsler Abbreviated Scale of Intelligence [WASI]; Wechsler, 2011)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Abbreviated Scale of Intelligence (WASI)"
Brief Visuospatial Memory Test – Revised (BVMT),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Visuospatial Memory Test – Revised (BVMT),performance test,all ages,No,,"the Brief Visuospatial Memory Test – Revised (BVMT, Immediate and Delayed 19 ; nonverbal declarative memory)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brief Visuospatial Memory Test – Revised (BVMT)"
Letter‐Number Sequencing task (LNS),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Letter‐Number Sequencing task (LNS),performance test,all ages,No,,the Letter‐Number Sequencing task (LNS 20 ; working memory),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Letter‐Number Sequencing task (LNS)"
Digit Cancellation,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Digit Cancellation,performance test,all ages,No,,Digit Cancellation (attention/inhibitory control) 21,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Digit Cancellation"
Hopkins Verbal Learning Test (HVLT),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Hopkins Verbal Learning Test (HVLT),performance test,all ages,No,,Hopkins Verbal Learning Test (HVLT; verbal declarative memory 22 ),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Hopkins Verbal Learning Test (HVLT)"
WISC‐III Object Assembly,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WISC‐III Object Assembly,performance test,pediatric,No,,WISC‐III Object Assembly (visuoconstructive ability) 23,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WISC‐III Object Assembly"
Achenbach Child Behavior Checklist (CBCL),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Achenbach Child Behavior Checklist (CBCL),questionnaire,pediatric,No,,Achenbach Child Behavior Checklist (CBCL; self‐ and parent‐report),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Achenbach Child Behavior Checklist (CBCL)"
Young Adult Self Report (YASR),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Young Adult Self Report (YASR),questionnaire,adult,No,,"Young Adult Self Report (YASR) 24 ,  25","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Young Adult Self Report (YASR)"
Neuropsychological Assessment Battery (NAB) Mazes,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Neuropsychological Assessment Battery (NAB) Mazes,performance test,all ages,No,,the Neuropsychological Assessment Battery (NAB) Mazes 26,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Neuropsychological Assessment Battery (NAB) Mazes"
Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,performance test,all ages,No,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency (category and letter fluency) 27,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency"
Behavior Rating Inventory of Executive Function (BRIEF),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Behavior Rating Inventory of Executive Function (BRIEF),questionnaire,all ages,No,,Behavior Rating Inventory of Executive Function (BRIEF; General Executive Composite (GEC) score) 28,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Behavior Rating Inventory of Executive Function (BRIEF)"
Spatial capacity working memory (SCAP) task,clinical_assessment_tools,PMID:28725547 | PMID:27081657,10.1016/j.nicl.2017.06.032 | 10.1002/acn3.288,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity. | A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Spatial capacity working memory (SCAP) task,performance test,adult,No,,"Participants viewed a visual array presenting 1, 3, 5, or 7 circles on the screen followed by a probe circle | A spatial working memory functional MRI paradigm, designed to be analogous to the behavioral tasks used in the mouse model","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Spatial capacity working memory (SCAP) task"
Hannover classification system,clinical_assessment_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Hannover classification system,scale,all ages,Yes,,Tumor size was classified by the Hannover and Koos classification systems,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Hannover classification system"
Koos classification system,clinical_assessment_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Koos classification system,scale,all ages,Yes,,Tumor size was classified by the Hannover and Koos classification systems,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Koos classification system"
RECIST guidelines,clinical_assessment_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,RECIST guidelines,scale,all ages,No,,"the maximum linear (tumor) diameter (MLD) in axial and coronal (medial to lateral and caudal to rostral/cranial, in total four measurements per MRI) planes were measured according to the RECIST guidelines","Assessment name not in title and 'tool' not in title — likely generic usage, not development: RECIST guidelines"
Tinnitus Functional Index,clinical_assessment_tools,PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tinnitus Functional Index,questionnaire,adult,No,,The Tinnitus Functional Index was identified as the most highly rated measure for the assessment of tinnitus in populations with neurofibromatosis type 2,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Tinnitus Functional Index"
Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),clinical_assessment_tools,PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),scale,clinician-rated,No,,The remaining 16 PROMs were submitted to a formal group review process using the Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE) form,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE)"
Client Oriented Scale of Improvement-Tinnitus,clinical_assessment_tools,PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.85,Citation Only,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Client Oriented Scale of Improvement-Tinnitus,scale,adult,Yes,,One measure was excluded (i.e. the Client Oriented Scale of Improvement-Tinnitus) because while it would be very useful for clinical settings,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Client Oriented Scale of Improvement-Tinnitus"
Brief Symptom Inventory 18 (BSI-18),clinical_assessment_tools,PMID:32572180 | PMID:28735371,10.1038/s41436-020-0873-7 | 10.1007/s10897-017-0128-1,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. | Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Symptom Inventory 18 (BSI-18),questionnaire,adult,No,18.0,"Emotional and behavioral problems were measured using the Brief Symptom Inventory 18 (BSI-18) for adult respondents | The BSI-18 (Derogatis et al., 2004) is an 18-item self-report measure to screen for psychological distress and psychiatric disorders in individuals in the community or hospital settings.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brief Symptom Inventory 18 (BSI-18)"
Behavior Problem Index (BPI),clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Behavior Problem Index (BPI),questionnaire,pediatric,No,,Emotional and behavioral problems were measured using...the Behavior Problem Index (BPI) for adolescents (<18 years of age),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Behavior Problem Index (BPI)"
CCSS Neurocognitive Questionnaire,clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CCSS Neurocognitive Questionnaire,questionnaire,adult,No,,"Neurocognitive outcomes were assessed for adult respondents with the CCSS Neurocognitive Questionnaire, which includes subscales measuring task efficiency, emotional regulation, organization, and memory","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CCSS Neurocognitive Questionnaire"
"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",scale,all ages,No,,"Chronic health conditions were classified and severity-graded according to the Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)"
Children's Tumor Foundation NF Registry,clinical_assessment_tools,PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Children's Tumor Foundation NF Registry,other,all ages,Yes,,The survey link was distributed via email to 1160 adolescent caregivers in the Children's Tumor Foundation NF Registry,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Children's Tumor Foundation NF Registry"
5-point Likert-type scales,clinical_assessment_tools,PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,5-point Likert-type scales,scale,pediatric,Yes,,Survey questions used 5-point Likert-type scales to measure ordered scale responses,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: 5-point Likert-type scales"
PEERS® intervention,clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PEERS® intervention,structured interview,pediatric,No,14.0,The PEERS® intervention was administered by certified PEERS® providers...according to the PEERS® manual and the CARD telehealth manual,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: PEERS® intervention"
Kaufman Brief Intelligence Test– Second Edition (KBIT-2),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Kaufman Brief Intelligence Test– Second Edition (KBIT-2),performance test,pediatric,No,,The KBIT-2 is a brief measure of cognitive abilities including verbal reasoning and nonverbal reasoning...administered at the adolescent intake appointment,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Kaufman Brief Intelligence Test– Second Edition (KBIT-2)"
Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,performance test,pediatric,No,,The WIAT-III Word Reading subtest examines the ability to accurately read words...administered at the adolescent intake appointment,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest"
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),structured interview,caregiver,No,,The KSADS is a semi-structured caregiver interview to assess psychopathology...administered at the pre-test appointment to a caregiver,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD)"
Social Communication Questionnaire (SCQ),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Communication Questionnaire (SCQ),questionnaire,caregiver,No,40.0,The SCQ is a caregiver-report questionnaire that examines ASD symptomatology...has 40 items that are rated as 'Yes' or 'No',"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Communication Questionnaire (SCQ)"
Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),questionnaire,all ages,No,51.0,The SSIS-SEL is a caregiver and self-report questionnaire measure examining social-emotional skills...Parent (51 items) and Student (46 items) forms,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Skills Improvement System Social-Emotional Learning (SSIS-SEL)"
Social Responsiveness Scale– Second Edition (SRS-2),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Responsiveness Scale– Second Edition (SRS-2),questionnaire,caregiver,No,65.0,The SRS-2 is a caregiver-report questionnaire of social impairment...includes 65 items that are rated on a 4-point scale,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Responsiveness Scale– Second Edition (SRS-2)"
Friendship Qualities Scale (FQS),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Friendship Qualities Scale (FQS),questionnaire,pediatric,No,23.0,The FQS is a self-report questionnaire examining the friendship qualities...rate 23 items using a 5-point scale,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Friendship Qualities Scale (FQS)"
Quality of Socialization Questionnaire (QSQ),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Quality of Socialization Questionnaire (QSQ),questionnaire,all ages,No,,The QSQ is a caregiver and self-report questionnaire to gather information about the adolescent's get-togethers with peers,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Quality of Socialization Questionnaire (QSQ)"
Test of Adolescent Social Skills Knowledge (TASSK),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Test of Adolescent Social Skills Knowledge (TASSK),questionnaire,pediatric,No,30.0,The TASSK is a self-report 30-item questionnaire that measures knowledge of specific social skills taught as part of the PEERS® intervention,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Test of Adolescent Social Skills Knowledge (TASSK)"
Pain Interference Index (PII),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index (PII),questionnaire,pediatric,No,6.0,The original PII measure is a six-item self-report questionnaire that assesses pain interference using the past 2 weeks as a recall period,Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Pain Interference Index-Parent report (PII-P),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index-Parent report (PII-P),questionnaire,caregiver,No,6.0,"The six-item PII-P is formatted and scored in the same manner as the self-report PII, with total scores ranging from 0 to 6",Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Modified Brief Pain Inventory (MBPI),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Modified Brief Pain Inventory (MBPI),questionnaire,pediatric,No,12.0,"The MBPI, adapted from the adult Brief Pain Inventory, is a 12-item self-report questionnaire that measures pain interference",Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Faces Pain Scale-Revised (FPS-R),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Faces Pain Scale-Revised (FPS-R),scale,pediatric,No,1.0,The FPS-R is a one-item tool designed to provide an overall indicator of pain intensity at the time of the assessment,Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Pain Rating Scale (PRS),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Rating Scale (PRS),scale,pediatric,No,2.0,The PRS is a two-item visual analogue scale (VAS) developed by the authors that assesses pain intensity,Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Pain Rating Scale-Parent version (PRS-P),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Rating Scale-Parent version (PRS-P),scale,caregiver,No,2.0,The Pain Rating Scale-Parent version (PRS-P) is similar to the VAS self-report PRS in terms of item content and format,Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
NF Disease Severity Scale,clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NF Disease Severity Scale,scale,clinician-rated,Yes,,"the NF Disease Severity Scale, adapted by our group from Ablon, asks the medical professional to rate the patient's symptoms as mild, moderate, or severe",Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
NF1 Disease Complications Scale,clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NF1 Disease Complications Scale,scale,clinician-rated,Yes,18.0,"the NF1 Disease Complications Scale, is a checklist designed by a multi-disciplinary team of medical experts in NF1 at the National Institutes of Health",Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Hematoxylin and eosin (H&E),clinical_assessment_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Hematoxylin and eosin (H&E),biomarker assay,clinician-rated,No,,Hematoxylin and eosin (H&E)-stained tissue sections from each tumor were reviewed by a board-certified pathologist,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Hematoxylin and eosin (H&E)"
immunohistochemical staining,clinical_assessment_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,immunohistochemical staining,biomarker assay,clinician-rated,Yes,,Patients from our institutional cohort with adequate tumor samples for immunohistochemical staining of DLK1,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: immunohistochemical staining"
NRS-11,clinical_assessment_tools,PMID:33442015 | PMID:40304934,10.1038/s41591-020-01193-6 | 10.1186/s41687-025-00877-2,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NRS-11,scale,all ages,No,11.0,"Numerical Rating Scale-11 (NRS-11): The NRS-11 is a self-report 11-point numeric scale that assesses pain intensity | The self-report NRS-11 has been used in numerous studies, including as a primary outcome measure, to assess pain intensity","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NRS-11"
BPI-PI Scale,clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BPI-PI Scale,questionnaire,all ages,No,7.0,Brief Pain Inventory (BPI)-Pain Interference (PI) Scale: The BPI-PI Scale is a 7-item self-report questionnaire that measures the extent to which pain interferes with daily functioning,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: BPI-PI Scale"
PedsQL™ NF1 Module,clinical_assessment_tools,PMID:23432799 | PMID:33442015,10.1186/1477-7525-11-21 | 10.1038/s41591-020-01193-6,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.",,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ NF1 Module,questionnaire,adult,Yes,74.0,"The objective of this study was to develop an NF1 HRQOL instrument as a module of PedsQL™ and to test for its initial feasibility, internal consistency reliability and validity in adults with NF1. | PedsQL™ NF1 Module: This scale is a self-report measure assessing NF1 disease-specific QOL. Participants who were ages 21 years and older completed the 74-item self-report adult questionnaire","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ NF1 Module"
FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),biomarker assay,all ages,No,,The FragEL™ DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21) was used according to manufacturer's instructions,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21)"
RECIST 1.1,clinical_assessment_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,RECIST 1.1,scale,adult,No,,radiographic tumor burden was quantified by sum of the longest tumor diameters (SLD) per RECIST 1.1 criteria,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: RECIST 1.1"
3-chamber social preference task,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,3-chamber social preference task,performance test,all ages,No,,The 3-chamber SP task occurred over 2 days as described previously,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: 3-chamber social preference task"
Open field test,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Open field test,performance test,all ages,No,,"mice were placed in the dark in an open chamber (40 × 40 cm, 30 cm height) for 60 minutes while activity was recorded","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Open field test"
Delay discounting task,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Delay discounting task,performance test,all ages,No,,mice were trained to identify which side of a T maze had a large reward (4 Cocoa Krispies) compared with the small reward (1 Cocoa Krispie),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Delay discounting task"
Cliff avoidance reaction test,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Cliff avoidance reaction test,performance test,all ages,No,,"a round, plastic platform (diameter, 20 cm; thickness, 2 cm) supported by a plastic rod (height, 50 cm) was used to assess the CAR","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Cliff avoidance reaction test"
PedsQL 4.0 Generic Core Scales,clinical_assessment_tools,PMID:22961690 | PMID:23432799,10.1002/pbc.24281 | 10.1186/1477-7525-11-21,"Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. | Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL 4.0 Generic Core Scales,questionnaire,pediatric,No,23.0,"QOL was assessed with the PedsQL 4.0 Generic Core Scales at baseline and prior to cycles 4, 8, 12, 18, and 24. This 23-item questionnaire yields subscale scores... | The NF1 HRQOL format, instructions, and Likert response scale are similar to the PedsQL™ 4.0 Generic Core Scales and other PedsQL™ Disease-Specific Modules.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL 4.0 Generic Core Scales"
PedsQL™ Arthritis Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Arthritis Module,questionnaire,all ages,Yes,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ Arthritis Module"
PedsQL™ Cancer Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Cancer Module,questionnaire,all ages,Yes,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ Cancer Module"
PedsQL™ Cerebral Palsy Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Cerebral Palsy Module,questionnaire,all ages,Yes,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ Cerebral Palsy Module"
PedsQL™ Family Impact Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Family Impact Module,questionnaire,caregiver,No,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ Family Impact Module"
Life Events Checklist (LEC),clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Life Events Checklist (LEC),questionnaire,adult,No,22.0,"Participants completed the Life Events Checklist, adapted from Elliott-DeSorbo et al. [ 30 ], to document stressful events in the past three months. The score is the number of stressful events endorsed (range 0–22).","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Life Events Checklist (LEC)"
PROMIS depression short form,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS depression short form,questionnaire,adult,No,8.0,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ].","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PROMIS depression short form"
PROMIS pain interference short form,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS pain interference short form,questionnaire,adult,No,6.0,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ].","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PROMIS pain interference short form"
PROMIS cognitive function short form,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS cognitive function short form,questionnaire,adult,No,8.0,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ].","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PROMIS cognitive function short form"
MEMS Cap,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MEMS Cap,performance test,adult,No,,"Participants' study drug bottles were fitted with a MEMS TM cap at baseline. Having been given instructions to take the drug 12 h apart, adherence was defined as opening the bottle 11–13 h since their last dose.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: MEMS Cap"
Barriers to Adherence Questionnaire,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Barriers to Adherence Questionnaire,questionnaire,adult,Yes,16.0,The barriers to adherence measure was created by the study team; participants were asked to think of times they missed a dose of their study drug in the past month and marked which of 16 possible reasons caused them to miss a dose.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Barriers to Adherence Questionnaire"
EuroQol (EQ 5D),clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EuroQol (EQ 5D),questionnaire,adult,No,5.0,"The EuroQol (EQ 5D) contains a global health score and covers Mobility, Self-care, Usual Activities, Pain/Discomfort, Anxiety and Depression","Assessment name not in title and 'tool' not in title — likely generic usage, not development: EuroQol (EQ 5D)"
Riccardi NF severity grade classification,clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Riccardi NF severity grade classification,scale,adult,Yes,4.0,Disease severity was determined using the Riccardi NF severity grade classification 1 to 4. Grades 1 and 2 were amalgamated to ensure adequate numbers in each group,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Riccardi NF severity grade classification"
NIH Consensus Development Conference 1987 diagnostic criteria,clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH Consensus Development Conference 1987 diagnostic criteria,structured interview,all ages,Yes,,Adults (18 years or older) who fulfilled the diagnostic criteria for NF1 (NIH Consensus Development Conference 1987) and attended the National NF1 service,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NIH Consensus Development Conference 1987 diagnostic criteria"
Impact of Pediatric Illness Scale,clinical_assessment_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Impact of Pediatric Illness Scale,scale,pediatric,No,,"...response of three or higher on a pain interference item (1–5 scales) from a self-report or parent-report QOL measure (Impact of Pediatric Illness Scale [ Wolters et al., 2010 ])","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Impact of Pediatric Illness Scale"
Pain Management Inventory,clinical_assessment_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,Development,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Management Inventory,scale,pediatric,Yes,,...two scales developed by the authors for the current study assessed pain management techniques used by the patients (Pain Management Inventory),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pain Management Inventory"
Post-Treatment Questionnaire,clinical_assessment_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,Development,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Post-Treatment Questionnaire,questionnaire,pediatric,Yes,,...treatment adherence and study satisfaction (Post-Treatment Questionnaire). Details on these measures are in Table I,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Post-Treatment Questionnaire"
visual analogue scale,clinical_assessment_tools,PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,visual analogue scale,scale,adult,No,,The inclusion criteria for the pain group were an average pain score of ≥ 3 on the visual analogue 0–10 scale over the previous 10 weeks,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: visual analogue scale"
NeuroConn DC-STIMULATOR MR,clinical_assessment_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NeuroConn DC-STIMULATOR MR,performance test,pediatric,No,,AtDCS was delivered via a NeuroConn DC-STIMULATOR MR with the anode placed over F3 position in the international 10–20 system,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NeuroConn DC-STIMULATOR MR"
Vineland Adaptive Behaviour Scale—third edition,clinical_assessment_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Vineland Adaptive Behaviour Scale—third edition,scale,caregiver,No,,Parent-rated Vineland Adaptive Behaviour Scale—third edition was administered to the parents to assess child adaptive behaviour,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Vineland Adaptive Behaviour Scale—third edition"
Conners 3 rating scale,clinical_assessment_tools,PMID:36316421 | PMID:35673329,10.1038/s41598-022-21907-9 | 10.1093/texcom/tgac021,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1. | Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners 3 rating scale,scale,caregiver,No,27.0,Conners 3 rating scale was used as a standardized measure for parent reported ADHD symptoms. It consists of 27 items each rated on a 4-point Likert scale | Conners 3 rating scale(Conners et al. 2011) was used as a standardized measure for parent reported ADHD symptoms. It consists of 27 items each rated on a 4-point Likert scale,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Conners 3 rating scale"
Wechsler Adult and Children Intelligence Scales,clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Adult and Children Intelligence Scales,performance test,all ages,No,,"All participants completed the age-appropriate digit-span subtest of the Wechsler Adult and Children Intelligence Scales (Wechsler, 2002, 2004)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Adult and Children Intelligence Scales"
Corsi block-tapping task,clinical_assessment_tools,PMID:27458360 | PMID:30192842,10.3389/fnhum.2016.00334 | 10.1371/journal.pone.0203520,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1. | Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Corsi block-tapping task,performance test,all ages,No,,"All participants completed...the Corsi block-tapping task (Kessels et al., 2000, 2008). Both are span tasks where the examiner presents a growing sequence | For working memory evaluation, we used the Digit Span according to the WAIS-III or WISC-III, and the Corsi block-tapping task","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Corsi block-tapping task"
Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),performance test,all ages,No,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III for adults and children,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III)"
School Achievement Test,clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,School Achievement Test,performance test,pediatric,No,,"We adopted the arithmetic subtest from the School Achievement Test (Stein, 1994), as an objective measure of school performance","Assessment name not in title and 'tool' not in title — likely generic usage, not development: School Achievement Test"
Brazilian Criterion for Economic Classification (CCEB),clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brazilian Criterion for Economic Classification (CCEB),questionnaire,adult,No,10.0,Socioeconomic status (SES) was assessed using the Brazilian Criterion for Economic Classification (CCEB) according to the criteria established,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brazilian Criterion for Economic Classification (CCEB)"
Ki-67/MIB-1 index,clinical_assessment_tools,PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,Ki-67/MIB-1 index,biomarker assay,adult,No,,"the meningioma recurrence score (MRS) generated by our machine learning algorithm revealed multiple predictive factors of recurrence, including age, female gender, and various histopathologic features, including the Ki-67/MIB-1 index.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Ki-67/MIB-1 index"
Rey complex figure test,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rey complex figure test,performance test,pediatric,No,,Rey complex figure test (CFT) (delayed recall; assessing nonverbal long-term memory),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rey complex figure test"
cancellation test,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,cancellation test,performance test,pediatric,No,,performance on the cancellation test (speed; assessing attention),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: cancellation test"
prism adaptation task,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,prism adaptation task,performance test,pediatric,No,,performance on a prism adaptation task (measurement of adaptation of the angle of hand movements in response to prism glass distortion),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: prism adaptation task"
Stroop color word test,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Stroop color word test,performance test,pediatric,No,,the Stroop color word test,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Stroop color word test"
Wechsler Intelligence Scale for Children–Revised,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scale for Children–Revised,scale,pediatric,No,,"assessed at baseline using the Wechsler Intelligence Scale for Children–Revised, Dutch version","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Intelligence Scale for Children–Revised"
Beery developmental test of visual-motor integration,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Beery developmental test of visual-motor integration,performance test,pediatric,No,,the Beery developmental test of visual-motor integration,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Beery developmental test of visual-motor integration"
judgment of line orientation task,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,judgment of line orientation task,performance test,pediatric,No,,and the judgment of line orientation task,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: judgment of line orientation task"
Numerical Rating Scale (NRS-11),clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Numerical Rating Scale (NRS-11),scale,pediatric,No,11.0,Children rated tumor pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable)...pain intensity (11-point Numerical Rating Scale [NRS-11]),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Numerical Rating Scale (NRS-11)"
Pain Interference Index,clinical_assessment_tools,PMID:32187457 | PMID:40304934,10.1056/NEJMoa1912735 | 10.1186/s41687-025-00877-2,Selumetinib in Children with Inoperable Plexiform Neurofibromas. | Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index,scale,pediatric,No,,"interference of pain in daily functioning (Pain Interference Index)...Scores on the Pain Interference Index range from 0 to 6, with higher scores indicating greater pain interference | provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pain Interference Index"
Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,questionnaire,pediatric,No,,"health-related quality of life (Pediatric Quality of Life Inventory [PedsQL] Generic Core Scales)...PedsQL scores range from 0 to 100, with higher scores indicating better health-related quality of life","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales"
Global Impression of Change scale,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Global Impression of Change scale,scale,pediatric,No,7.0,perceived changes with treatment (Global Impression of Change scale)...Scores on the Global Impression of Change scale range from 1 (very much improved) to 7 (very much worse),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Global Impression of Change scale"
Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,questionnaire,pediatric,No,,children and parents also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility and Upper Extremity short forms to assess physical functioning,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form"
Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,questionnaire,pediatric,No,,children and parents also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility and Upper Extremity short forms to assess physical functioning,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form"
"NCI Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"NCI Common Terminology Criteria for Adverse Events, version 4.0",scale,all ages,No,,"Adverse events were graded with the use of the NCI Common Terminology Criteria for Adverse Events, version 4.0","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NCI Common Terminology Criteria for Adverse Events, version 4.0"
volumetric magnetic resonance imaging analysis,clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,volumetric magnetic resonance imaging analysis,biomarker assay,pediatric,Yes,,Response to treatment was monitored by using volumetric magnetic resonance imaging analysis to measure the change in size of the plexiform neurofibroma,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: volumetric magnetic resonance imaging analysis"
Responsibility for Medication Questionnaire,clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Responsibility for Medication Questionnaire,questionnaire,pediatric,No,,Adherence to the dosing schedule was assessed by administration of the Responsibility for Medication Questionnaire,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Responsibility for Medication Questionnaire"
National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,clinical_assessment_tools,PMID:37174087 | PMID:28029918,10.3390/cancers15092621 | 10.1056/NEJMoa1605943,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study. | Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,scale,all ages,No,,"...Adverse events (AE) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0... | Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0","Assessment name not in title and 'tool' not in title — likely generic usage, not development: National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0"
Response Evaluation Criteria In Solid Tumors (RECIST),clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Response Evaluation Criteria In Solid Tumors (RECIST),scale,all ages,No,,The use of standard response criteria (Response Evaluation Criteria In Solid Tumors [RECIST] and World Health Organization [WHO] criteria),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Response Evaluation Criteria In Solid Tumors (RECIST)"
World Health Organization (WHO) criteria,clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,World Health Organization (WHO) criteria,scale,all ages,No,,The use of standard response criteria (Response Evaluation Criteria In Solid Tumors [RECIST] and World Health Organization [WHO] criteria),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: World Health Organization (WHO) criteria"
CNC-word test,clinical_assessment_tools,PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CNC-word test,performance test,pediatric,No,,Speech perception ability in background noise was evaluated in device-active and inactive conditions using the CNC-word test.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: CNC-word test"
LIFE-R Questionnaire,clinical_assessment_tools,PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,LIFE-R Questionnaire,questionnaire,pediatric,No,,Listening and communication ratings (LIFE-R Questionnaire) were obtained at baseline and at the end of each treatment phase.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: LIFE-R Questionnaire"
Rex Gauge durometer,clinical_assessment_tools,PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Rex Gauge durometer,performance test,all ages,Yes,,One was the Rex Gauge durometer (REX) produced by Rex Gauge LLC...used to measure cNF stiffness,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rex Gauge durometer"
Delfin SkinFibroMeter,clinical_assessment_tools,PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Delfin SkinFibroMeter,performance test,all ages,Yes,,"the other was the SkinFibroMeter (DEFLIN) made by Delfin Technologies...measure tissue induration, assessing tissue stiffness in quantitative units","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Delfin SkinFibroMeter"
Vectra H1,clinical_assessment_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Vectra H1,performance test,adult,Yes,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: Vectra H1 (Canfield Scientific Inc, Fairfield, NJ, USA)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Vectra H1"
LifeViz Micro,clinical_assessment_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,LifeViz Micro,performance test,adult,Yes,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: LifeViz Micro (QuantifiCare, Biot, France)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: LifeViz Micro"
Cherry Imaging,clinical_assessment_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Cherry Imaging,performance test,adult,Yes,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: Cherry Imaging (Yokneam, Israel)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Cherry Imaging"
nerve conduction velocity,clinical_assessment_tools,PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,nerve conduction velocity,performance test,all ages,No,,"By measuring nerve properties as conduction velocity or potential amplitudes of the signal, it is possible to characterize the origin of peripheral nerve diseases.",Publication title lacks NF-specific terms: A neuronal function of the tumor suppressor protein merlin.
electrophysiological measurements,clinical_assessment_tools,PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,electrophysiological measurements,performance test,all ages,No,,Electrophysiological measurements are an indispensable tool for investigating the functional integrity of peripheral nerves in both the clinical and laboratory environment.,Publication title lacks NF-specific terms: A neuronal function of the tumor suppressor protein merlin.
Morris water maze,clinical_assessment_tools,PMID:25917366 | PMID:24375753,10.1038/mp.2015.48 | 10.1002/ana.24093,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Morris water maze,performance test,all ages,No,,The water maze task was performed as previously described. Before performing the water maze task | Morris Water Maze testing for spatial learning and memory was conducted as previously described,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Morris water maze"
Rotarod,clinical_assessment_tools,PMID:25917366 | PMID:32839340,10.1038/mp.2015.48 | 10.1073/pnas.2008391117,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. | Brain-wide structural and functional disruption in mice with oligodendrocyte-specific,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rotarod,performance test,all ages,No,,"Motor learning was assessed with the accelerating rotarod (Ugo Basile, Comerio Varese, Italy) | Gross motor coordination function was evaluated using the Rotarod (Med Associates)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rotarod"
EGI 128-electrode Hydrocel Sensor Net,clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EGI 128-electrode Hydrocel Sensor Net,biomarker assay,pediatric,No,,"We recorded EEG data with an EGI (Philips Neuro, Oregon, USA) 128-electrode Hydrocel Sensor Net, with the vertex electrode...","Assessment name not in title and 'tool' not in title — likely generic usage, not development: EGI 128-electrode Hydrocel Sensor Net"
Mullen Scales of Early Learning (MSEL),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Mullen Scales of Early Learning (MSEL),scale,pediatric,No,,The Mullen Scales of Early Learning (MSEL) is a standardised measure that assesses developmental ability across five domains...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Mullen Scales of Early Learning (MSEL)"
Autism Observation Score for Infants (AOSI),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Observation Score for Infants (AOSI),structured interview,pediatric,Yes,,The Autism Observation Score for Infants (AOSI) is a standardised research assessment that examines ASD traits in infants...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Autism Observation Score for Infants (AOSI)"
Infant Behaviour Questionnaire-Revised (IBQ-R),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Infant Behaviour Questionnaire-Revised (IBQ-R),questionnaire,caregiver,No,191.0,The IBQ-R is a parent-report questionnaire consisting of 191 items and 14 scales that relate to different aspects of infant temperament...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Infant Behaviour Questionnaire-Revised (IBQ-R)"
MacArthur Bates Communicative Development Inventory (CDI),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MacArthur Bates Communicative Development Inventory (CDI),questionnaire,caregiver,No,800.0,Parents completed the MacArthur Bates Communicative Development Inventory (CDI) long form measures early language abilities...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: MacArthur Bates Communicative Development Inventory (CDI)"
NIH consensus criteria,clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH consensus criteria,structured interview,all ages,Yes,,All participants had their diagnosis confirmed via molecular testing of cord blood samples or clinical diagnosis based on NIH consensus criteria,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NIH consensus criteria"
"International Classification of Diseases, 10th Revision (ICD-10)",clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"International Classification of Diseases, 10th Revision (ICD-10)",scale,all ages,No,,"a strong positive COVID-19 diagnostic code from the International Classification of Diseases, 10th Revision (ICD-10)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: International Classification of Diseases, 10th Revision (ICD-10)"
Systematized Nomenclature of Medicine (SNOMED),clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Systematized Nomenclature of Medicine (SNOMED),scale,all ages,No,,"diagnostic code from the International Classification of Diseases, 10th Revision (ICD-10) or Systematized Nomenclature of Medicine (SNOMED) tables","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Systematized Nomenclature of Medicine (SNOMED)"
Logical Observation Identifiers Names and Codes (LOINC),clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Logical Observation Identifiers Names and Codes (LOINC),scale,all ages,No,,"NF1-relevant diagnosis codes from SNOMED, ICD-9/10, Logical Observation Identifiers Names and Codes (LOINC), and Nebraska Lexicon","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Logical Observation Identifiers Names and Codes (LOINC)"
Nebraska Lexicon,clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nebraska Lexicon,scale,all ages,No,,"NF1-relevant diagnosis codes from SNOMED, ICD-9/10, Logical Observation Identifiers Names and Codes (LOINC), and Nebraska Lexicon","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Nebraska Lexicon"
NFTI-QOL,clinical_assessment_tools,PMID:24619350 | PMID:32642740,10.1007/s00415-014-7303-1 | 10.1093/noajnl/vdaa003,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. | Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NFTI-QOL,questionnaire,adult,Yes,8.0,The disease-focused NF2 impact on quality of life (NFTI-QOL) patient questionnaire was assessed as an outcome measure for treatment in a multi-centre study. | disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NFTI-QOL"
"mouse cytokine array (panel A, R&D system)",clinical_assessment_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse cytokine array (panel A, R&D system)",biomarker assay,all ages,No,,"Mouse cytokine protein expressions were quantified using mouse cytokine array (panel A, R&D system, Minneapolis, MN)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: mouse cytokine array (panel A, R&D system)"
NIH Consensus Conference criteria,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH Consensus Conference criteria,scale,all ages,Yes,,"...ages ≤ 25 years with a diagnosis of NF1, as defined by the NIH Consensus Conference criteria [19]...","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NIH Consensus Conference criteria"
Lansky performance status,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lansky performance status,scale,pediatric,No,,...Exclusion criteria included Lansky or Karnofsky performance statuses of less than 60...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Lansky performance status"
Karnofsky performance status,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Karnofsky performance status,scale,adult,No,,...Exclusion criteria included Lansky or Karnofsky performance statuses of less than 60...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Karnofsky performance status"
Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),scale,all ages,Yes,,...Analysis of functional responses for the cohort of participants with airway involvement were guided by the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) sleep and pulmonary outcomes recommendations...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS)"
Autism Diagnostic Interview Revised (ADI-R),clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Interview Revised (ADI-R),structured interview,pediatric,No,87.0,meeting ASD cut-off on the Autism Diagnostic Interview Revised (ADI-R)...Autism Diagnostic Interview-Revised (ADI-R) was used for detailed parent interviews,Publication title lacks NF-specific terms: Autism Spectrum Disorder Symptom Profile Across the RASopathies.
Autism Diagnostic Observation Schedule-2 (ADOS-2),clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Observation Schedule-2 (ADOS-2),structured interview,pediatric,No,4.0,scoring above the ASD cut-off on the Autism Diagnostic Observation Schedule-2 (ADOS-2)...The Autism Diagnostic Observation Schedule–second edition (ADOS-2) was used to measure current autism clinical profile,Publication title lacks NF-specific terms: Autism Spectrum Disorder Symptom Profile Across the RASopathies.
Wechsler Abbreviated Scale of Intelligence-II (WASI-II),clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Abbreviated Scale of Intelligence-II (WASI-II),performance test,pediatric,No,,"The Wechsler Abbreviated Scale of Intelligence-II (WASI-II) was used to measure verbal intellectual functioning (VIQ), based on two subscales called Similarities and Vocabulary",Publication title lacks NF-specific terms: Autism Spectrum Disorder Symptom Profile Across the RASopathies.
"Conners Parent Rating Scale (3rd edition, short form)",clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Conners Parent Rating Scale (3rd edition, short form)",scale,caregiver,No,,"Conners Parent Rating Scale (3rd edition, short form) measured ADHD symptomatology. The two domains, inattention and hyperactivity, were used in the study and presented in T-score",Publication title lacks NF-specific terms: Autism Spectrum Disorder Symptom Profile Across the RASopathies.
Magnetom Avanto,clinical_assessment_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Magnetom Avanto,biomarker assay,all ages,Yes,,"All MRI sequences were performed on a 1.5 T scanner (Magnetom Avanto, Siemens Healthineers, Erlangen, Germany)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Magnetom Avanto"
"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",scale,adult,No,,"same measures from the Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV; Wechsler, 2014) for the healthy controls","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)"
University of Maryland Letter–Number Sequencing (LNS) task,clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,University of Maryland Letter–Number Sequencing (LNS) task,performance test,adult,No,,"Working memory capacity was measured behaviorally using the University of Maryland Letter–Number Sequencing (LNS) task (Gold et al., 1997)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: University of Maryland Letter–Number Sequencing (LNS) task"
Vineland Adaptive Behaviour Scale (VABS-III),clinical_assessment_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Vineland Adaptive Behaviour Scale (VABS-III),scale,caregiver,No,,parent-reported Adaptive Behaviour Composite (ABC) scores on the Vineland Adaptive Behaviour Scale (VABS-III),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Vineland Adaptive Behaviour Scale (VABS-III)"
adaptive auditory n-back task,clinical_assessment_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,adaptive auditory n-back task,performance test,pediatric,No,,"performance on an adaptive auditory n-back task, and performance on a non-adaptive visual n-back task performed during EEG","Assessment name not in title and 'tool' not in title — likely generic usage, not development: adaptive auditory n-back task"
non-adaptive visual n-back task,clinical_assessment_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,non-adaptive visual n-back task,performance test,pediatric,No,,"performance on an adaptive auditory n-back task, and performance on a non-adaptive visual n-back task performed during EEG","Assessment name not in title and 'tool' not in title — likely generic usage, not development: non-adaptive visual n-back task"
Brief Pain Inventory Short Form (BPI-SF),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Pain Inventory Short Form (BPI-SF),questionnaire,adult,No,,responses to the Brief Pain Inventory Short Form (BPI-SF) [ 8 ]...a pain severity aggregate score of ≥3 on the BPI-SF [ 8 ] for pain experienced in the previous 2 weeks,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brief Pain Inventory Short Form (BPI-SF)"
Patient Health Questionnaire (PHQ),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient Health Questionnaire (PHQ),questionnaire,adult,No,,responses to...Patient Health Questionnaire (PHQ) [ 19 ]...evidence of moderate to severe depression or anxiety on the PHQ or GAD-7,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient Health Questionnaire (PHQ)"
Structured Clinical Interview for DSM Self Report version (SCID-SR),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Structured Clinical Interview for DSM Self Report version (SCID-SR),structured interview,adult,No,,Structured Clinical Interview for DSM Self Report version (SCID-SR) [ 20 ]...evidence of psychosis or schizophrenia on the SCID-SR [ 20 ],"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Structured Clinical Interview for DSM Self Report version (SCID-SR)"
Generalized Anxiety Disorder 7 Item version (GAD-7),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Generalized Anxiety Disorder 7 Item version (GAD-7),scale,adult,No,7.0,Generalized Anxiety Disorder 7 Item version (GAD-7) [ 21 ]...evidence of moderate to severe depression or anxiety on the PHQ or GAD-7,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Generalized Anxiety Disorder 7 Item version (GAD-7)"
PHQ-9,clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PHQ-9,questionnaire,adult,No,9.0,The PHQ-9 and GAD-7 are copyrighted by Pfizer Inc. and are freely available for research and clinical use,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: PHQ-9"
Social Responsiveness Scale 2nd Edition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Responsiveness Scale 2nd Edition,scale,caregiver,No,65.0,Children with NF1 that screen at risk for ASD on the parent-rated Social Responsiveness Scale 2nd Edition will be invited back to complete...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Responsiveness Scale 2nd Edition"
Autism Diagnostic Observation Scale 2nd Edition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Observation Scale 2nd Edition,structured interview,pediatric,Yes,,complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised to determine whether they fulfil ASD diagnostic criteria,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Autism Diagnostic Observation Scale 2nd Edition"
Autism Diagnostic Interview-Revised,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Interview-Revised,structured interview,caregiver,Yes,95.0,complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised to determine whether they fulfil ASD diagnostic criteria,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Autism Diagnostic Interview-Revised"
WPPSI-IV,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WPPSI-IV,performance test,pediatric,No,,WPPSI-IV 10 subtests providing 5 indices and full scale IQ Y,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WPPSI-IV"
WISC-V,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WISC-V,performance test,pediatric,No,,WISC-V 10 subtests providing 5 indices and full scale IQ S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WISC-V"
TEA-Ch Sky Search,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TEA-Ch Sky Search,performance test,pediatric,No,,TEA-Ch Sky Search Assessing the ability to selectively attend to and identify 20 visual targets among distractors S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: TEA-Ch Sky Search"
TEA-Ch Score!,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TEA-Ch Score!,performance test,pediatric,No,,TEA-Ch Score! 10 trials assessing the ability to sustain attention by mentally counting aurally administered tones S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: TEA-Ch Score!"
Shape School,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Shape School,performance test,pediatric,No,60.0,"Shape School 4 conditions (each with 15 items) assessing inhibition, task-switching and working memory abilities","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Shape School"
NEPSY-II Inhibition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II Inhibition,performance test,pediatric,No,6.0,NESPY-II Inhibition 6 items assessing the ability to inhibit automatic responses in favour of novel responses,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NEPSY-II Inhibition"
Tower of Hanoi,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tower of Hanoi,performance test,pediatric,No,6.0,"Tower of Hanoi 6 items assessing set shifting, response inhibition, working memory and the ability to hold a set of rules in mind","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Tower of Hanoi"
TEA-Ch Creature Counting,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TEA-Ch Creature Counting,performance test,pediatric,No,,TEA-Ch Creature Counting 7 trials assessing the ability to accurately switch and redirect attention to count up/down S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: TEA-Ch Creature Counting"
WIAT-II Abbreviated,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WIAT-II Abbreviated,performance test,pediatric,No,,"WIAT-II Abbreviated 3 subtests assessing numerical operations, spelling and single word reading S","Assessment name not in title and 'tool' not in title — likely generic usage, not development: WIAT-II Abbreviated"
NEPSY-II Affect Recognition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II Affect Recognition,performance test,pediatric,No,36.0,NEPSY-II Affect Recognition 36 items assessing the ability to match facial expressions from photographs of children's faces,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NEPSY-II Affect Recognition"
Benton Facial Recognition Test,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Benton Facial Recognition Test,performance test,pediatric,No,13.0,Benton Facial Recognition Test 13 items assessing the ability to recognise a target face from a selection of distractors S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Benton Facial Recognition Test"
NEPSY-II ToM,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II ToM,performance test,pediatric,No,21.0,"NEPSY-II ToM 21 items assessing the ability to comprehend the perspectives, intentions and beliefs of another person","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NEPSY-II ToM"
Reading the Mind in the Eyes Test-Child,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Reading the Mind in the Eyes Test-Child,performance test,pediatric,No,28.0,Reading the Mind in the Eyes Test-Child 28 items assessing the ability to determine a person's thoughts or feelings based on a picture of only their eyes,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Reading the Mind in the Eyes Test-Child"
Faux Pas Task,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Faux Pas Task,performance test,pediatric,No,20.0,Faux Pas Task 20 short stories assessing the ability to identify a social faux pas S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Faux Pas Task"
Strange Stories,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Strange Stories,performance test,pediatric,No,14.0,"Strange Stories 14 short stories assessing the ability to attribute mental states (eg, desires, beliefs or intentions)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Strange Stories"
CELF-Preschool-2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CELF-Preschool-2,performance test,pediatric,No,,"CELF-Preschool-2 2 subtests assessing knowledge of grammatical rules in a sentence completion task and the ability to name objects, people and activities Y","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CELF-Preschool-2"
CELF-4 Formulated Sentences,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CELF-4 Formulated Sentences,performance test,pediatric,No,28.0,CELF-4 Formulated Sentences 28 items assessing the ability to formulate semantically and grammatically correct spoken sentences,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: CELF-4 Formulated Sentences"
NEPSY-II Comprehension of Instructions,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II Comprehension of Instructions,performance test,pediatric,No,33.0,NEPSY-II Comprehension of Instructions 33 items assessing the ability to comprehend and follow multistep instructions of increasing complexity,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NEPSY-II Comprehension of Instructions"
SRS-2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,SRS-2,scale,caregiver,Yes,65.0,"SRS-2 65 items assessing the presence and severity of ASD symptoms including social awareness, social cognition, social communication","Assessment name not in title and 'tool' not in title — likely generic usage, not development: SRS-2"
CADS,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CADS,scale,caregiver,No,26.0,CADS 26 items assessing ADHD symptoms of impulsivity/hyperactivity and inattention Y,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: CADS"
Conners 3,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners 3,scale,caregiver,No,110.0,Conners 3 110 items assessing ADHD symptom and comorbid disorders including oppositional defiant and conduct problems,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Conners 3"
BRIEF-Preschool,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BRIEF-Preschool,scale,caregiver,No,63.0,"BRIEF-Preschool 63 items assessing executive functions within the home environment, including working memory, mental set shifting","Assessment name not in title and 'tool' not in title — likely generic usage, not development: BRIEF-Preschool"
BRIEF,clinical_assessment_tools,PMID:34377779 | PMID:31558455,10.1212/NXG.0000000000000616 | 10.1136/bmjopen-2019-030601,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1. | Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BRIEF,questionnaire,caregiver,No,,"observer-reported functioning (BRIEF) were the primary outcomes...Behavior Rating Inventory of Executive Function; BRIEF | BRIEF 86 items assessing executive functions in the home environment, including working memory, mental set shifting, response inhibition","Assessment name not in title and 'tool' not in title — likely generic usage, not development: BRIEF"
ABAS-3: 0–5 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ABAS-3: 0–5 years,scale,caregiver,No,241.0,"ABAS-3: 0–5 years 241 items assessing adaptive functioning skills, including communication, community use, preacademics","Assessment name not in title and 'tool' not in title — likely generic usage, not development: ABAS-3: 0–5 years"
ABAS-3: 5–21 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ABAS-3: 5–21 years,scale,caregiver,No,232.0,"ABAS-3: 5–21 years 232 items assessing adaptive functioning skills, including communication, community use, functional academics","Assessment name not in title and 'tool' not in title — likely generic usage, not development: ABAS-3: 5–21 years"
SSIS Rating Scale,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SSIS Rating Scale,scale,caregiver,No,79.0,"SSIS Rating Scale 79 items assessing social skills, problem behaviours and academic competence Y, S","Assessment name not in title and 'tool' not in title — likely generic usage, not development: SSIS Rating Scale"
Sensory Profile 2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Sensory Profile 2,scale,caregiver,No,86.0,"Sensory Profile 2 86 items assessing sensory processing, including auditory, visual, taste/smell, movement, body position, touch","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Sensory Profile 2"
CBCL: 1.5–5 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CBCL: 1.5–5 years,scale,caregiver,No,100.0,"CBCL: 1.5–5 years 100 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CBCL: 1.5–5 years"
CBCL: 6–18 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CBCL: 6–18 years,scale,caregiver,No,113.0,"CBCL: 6–18 years 113 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CBCL: 6–18 years"
CCC-2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CCC-2,scale,caregiver,No,70.0,"CCC-2 70 items assessing speech, syntax, semantics, coherence, inappropriate initiation, stereotyped language, use of context","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CCC-2"
MEGA-PRESS,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MEGA-PRESS,biomarker assay,pediatric,No,,"acquire two GABA-edited magnetic resonance spectra using the localised spectroscopy sequence MEGA-PRESS, developed by CMRR","Assessment name not in title and 'tool' not in title — likely generic usage, not development: MEGA-PRESS"
n-back task,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,n-back task,performance test,pediatric,No,24.0,Verbal and visuospatial working memory was assessed using the n-back task. The task was programmed in-house using E-Prime software.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: n-back task"
Corsi block task,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Corsi block task,performance test,pediatric,No,,Memory span was assessed using a computerized Corsi block task on the Psychology Experiment Building Language (PEBL),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Corsi block task"
Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),performance test,pediatric,No,,Auditory working memory was assessed using the digit span forward and back task of the Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV)"
Vineland Adaptive Behavior Scale—third edition,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Vineland Adaptive Behavior Scale—third edition,scale,caregiver,No,,Parent-rated Vineland Adaptive Behavior Scale—third edition (Hill et al. 2017) was administered to the parents to assess child adaptive behavior,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Vineland Adaptive Behavior Scale—third edition"
Nottingham Health Profile (NHP),clinical_assessment_tools,PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nottingham Health Profile (NHP),questionnaire,adult,No,38.0,The Nottingham Health Profile (NHP) questionnaire was used as comparator questionnaire to evaluate convergent validity...consists of 38 items that cover six subsections,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Nottingham Health Profile (NHP)"
WAIS-III,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WAIS-III,performance test,adult,No,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WAIS-III"
WISC-III,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WISC-III,performance test,pediatric,No,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WISC-III"
Nine-Hole Peg Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nine-Hole Peg Test,performance test,all ages,No,,The Nine-Hole Peg Test was performed as a measure of finger dexterity. It measures the time (in seconds) needed to complete the test,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Nine-Hole Peg Test"
Rey-Osterrieth Complex Figure Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rey-Osterrieth Complex Figure Test,performance test,all ages,No,,The Rey-Osterrieth Complex Figure Test was implemented as a measure of the visuospatial cognitive domain,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rey-Osterrieth Complex Figure Test"
Rey Auditory-Verbal Learning Test (RAVLT),clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rey Auditory-Verbal Learning Test (RAVLT),performance test,all ages,No,,Immediate (A6) and delayed recalls (A7) of the Brazilian-Portuguese version of the Rey Auditory-Verbal Learning Test (RAVLT) were taken as measures of verbal episodic memory,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rey Auditory-Verbal Learning Test (RAVLT)"
Category Fluency Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Category Fluency Test,performance test,all ages,No,,"Assessment of this cognitive domain was performed by a Category Fluency Test (""animals"")","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Category Fluency Test"
Lexical Fluency Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lexical Fluency Test,performance test,all ages,No,,"and by Lexical Fluency Test letters (F, A, and S)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Lexical Fluency Test"
Five Digits Test (FDT),clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Five Digits Test (FDT),performance test,all ages,No,,The Five Digits Test (FDT) is a numeric-Stroop paradigm designed to assess attentional processes,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Five Digits Test (FDT)"
Tower of London Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tower of London Test,performance test,all ages,No,,The Tower of London Test was used as a measure of Planning Skills,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Tower of London Test"
GE Discovery 690,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,GE Discovery 690,biomarker assay,all ages,No,,"Resting-state 18F-FDG PET/CT brain images were acquired in a GE Discovery 690 (GE Healthcare, Millwalke, EUA) scanner","Assessment name not in title and 'tool' not in title — likely generic usage, not development: GE Discovery 690"
UK NF2 Genetic Severity Score,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,UK NF2 Genetic Severity Score,scale,all ages,Yes,3.0,We have assessed NF2 clinical phenotype in 142 patients in relation to the UK NF2 Genetic Severity Score to validate its use as a clinical and research tool,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: UK NF2 Genetic Severity Score"
8-item NF2 disease-specific quality of life score,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,8-item NF2 disease-specific quality of life score,questionnaire,all ages,Yes,8.0,"Quality of life was assessed using the 8-item NF2 disease-specific quality of life score (0–24), with good internal reliability (Cronbach's α=0.87)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: 8-item NF2 disease-specific quality of life score"
hearing grade score,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,hearing grade score,scale,all ages,Yes,6.0,"Hearing grade was assigned based on a score of 1–6, as used within the English NF2 service to indicate suitability for a hearing implant","Assessment name not in title and 'tool' not in title — likely generic usage, not development: hearing grade score"
Manchester NF2 diagnostic criteria,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Manchester NF2 diagnostic criteria,structured interview,all ages,Yes,,all patients known to the Oxford NF2 centre who met the Manchester NF2 diagnostic criteria and consented to genetic testing were analysed,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Manchester NF2 diagnostic criteria"
Noldus Cat-Walk XT system,clinical_assessment_tools,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Noldus Cat-Walk XT system,performance test,all ages,No,,Gait was analyzed using the Noldus Cat-Walk XT system as before,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Noldus Cat-Walk XT system"
Wechsler Intelligence Scale for Children (WISC-III),clinical_assessment_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scale for Children (WISC-III),performance test,pediatric,No,,"We administered the Portuguese adapted version of the Wechsler Intelligence Scale for Children (WISC-III), in all participants with NF1","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Intelligence Scale for Children (WISC-III)"
Diamond Digital color monitor (Mitsubishi Electric Australia),clinical_assessment_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,Diamond Digital color monitor (Mitsubishi Electric Australia),performance test,pediatric,No,,"The stimuli were presented in a CRT monitor (Diamond Digital color monitor, Mitsubishi Electric Australia, Rydalmere, NSW, Australia)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Diamond Digital color monitor (Mitsubishi Electric Australia)"
Manchester Criteria,clinical_assessment_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Manchester Criteria,scale,all ages,Yes,,"patients who fitted Manchester Criteria for NF2 disease (Table S1 ) (Evans et al., 1992 ; Smith et al., 2017 ) were considered to have phenotypic specificity","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Manchester Criteria"
MC-780MA Tanita Tokyo body composition analyzer,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MC-780MA Tanita Tokyo body composition analyzer,performance test,pediatric,No,,Body fat was measured using the MC‐780MA Tanita Tokyo body composition analyzer. The MC‐780MA body composition analyzer divides the human body into five sections,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: MC-780MA Tanita Tokyo body composition analyzer"
Citec hand-held dynamometer,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Citec hand-held dynamometer,performance test,pediatric,No,,"Maximal isometric strength of three muscle groups involved in prime movements, including grip strength, ankle dorsiflexion, and plantarflexion were tested using hand‐held dynamometry","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Citec hand-held dynamometer"
Handwriting Speed Test,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Handwriting Speed Test,performance test,pediatric,No,,"Fine motor endurance was evaluated by the Handwriting Speed Test (Wallen et al., 1996) that gives a raw score in letters per minute","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Handwriting Speed Test"
6-minute-walk test,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,6-minute-walk test,performance test,pediatric,No,,"gross motor endurance by the 6MWT, which was completed barefoot on a point‐to‐point, 25‐m long, flat, straight, hard surfaced track","Assessment name not in title and 'tool' not in title — likely generic usage, not development: 6-minute-walk test"
PedsQL Generic 4.0,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL Generic 4.0,questionnaire,caregiver,No,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL Generic 4.0"
PedsQL Neuromuscular 3.0,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL Neuromuscular 3.0,questionnaire,caregiver,Yes,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL Neuromuscular 3.0"
CBCL/6-18,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CBCL/6-18,questionnaire,caregiver,No,113.0,"The Child Behavior Checklist for ages 6–18 or CBCL/6‐18 (©ASEBA 2020). The CBCL/6‐18 (©ASEBA 2020) consists of 113 questions, scored on a 3‐point Likert scale","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CBCL/6-18"
Wechsler Intelligence Scale,clinical_assessment_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scale,scale,pediatric,No,,Participants completed age-appropriate versions of the Wechsler Intelligence Scale,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
A Developmental NEuroPSYchological Assessment (NEPSY-II),clinical_assessment_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,A Developmental NEuroPSYchological Assessment (NEPSY-II),performance test,pediatric,No,,select subtests from A Developmental NEuroPSYchological Assessment (NEPSY-II),Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
Tanner staging,clinical_assessment_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tanner staging,scale,pediatric,No,,Pubertal status was assessed by an experienced physician using Tanner staging,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
Numeric Rating Scale-11,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Numeric Rating Scale-11,scale,all ages,No,1.0,provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Numeric Rating Scale-11"
PII,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PII,questionnaire,all ages,No,6.0,The PII is a 6-item questionnaire developed to assess the extent to which pain interferes with six different aspects of daily functioning,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: PII"
PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),scale,all ages,Yes,,"the measures' instructions, items, and formatting were modified to create the PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF)"
Pain Interference Index for plexiform neurofibromas (PII-pNF),clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index for plexiform neurofibromas (PII-pNF),questionnaire,all ages,Yes,,"the measures' instructions, items, and formatting were modified to create the PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF) and the Pain Interference Index for plexiform neurofibromas (PII-pNF)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pain Interference Index for plexiform neurofibromas (PII-pNF)"
HPLC/MS/MS method,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,HPLC/MS/MS method,biomarker assay,pediatric,No,,Sorafenib plasma concentrations were measured using a validated HPLC/MS/MS method,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: HPLC/MS/MS method"
H-score,clinical_assessment_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,H-score,scale,all ages,No,,We used the H-score for quantification of FAP immunohistochemistry: 1 × percentage of weak staining) + (2 × percentage of moderate staining) + (3 × percentage of strong staining). The H score ranges from 0 to 300,Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
PROMIS pain interference short form 8a,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS pain interference short form 8a,questionnaire,adult,No,8.0,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PROMIS pain interference short form 8a"
PedsQL NF1 adult module,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL NF1 adult module,questionnaire,adult,Yes,74.0,disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL NF1 adult module"
Ablon visibility index,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Ablon visibility index,scale,clinician-rated,Yes,,clinicians also rated the disease visibility using the Ablon visibility index,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Ablon visibility index"
House and Brackmann facial nerve scale,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,House and Brackmann facial nerve scale,scale,clinician-rated,No,6.0,physicians also completed the House and Brackmann facial nerve scale that rates facial nerve impairments from 1—normal symmetric function to 6—indicating complete paralysis,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: House and Brackmann facial nerve scale"
Ras activation assay (Millipore),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Ras activation assay (Millipore),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Ras activation assay (Millipore)"
cAMP assay (New East Biosciences),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,cAMP assay (New East Biosciences),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements","Assessment name not in title and 'tool' not in title — likely generic usage, not development: cAMP assay (New East Biosciences)"
TUNEL assay (Roche Diagnostics),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TUNEL assay (Roche Diagnostics),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements","Assessment name not in title and 'tool' not in title — likely generic usage, not development: TUNEL assay (Roche Diagnostics)"
dopamine assay (Rocky Mountain Diagnostics),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,dopamine assay (Rocky Mountain Diagnostics),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements","Assessment name not in title and 'tool' not in title — likely generic usage, not development: dopamine assay (Rocky Mountain Diagnostics)"
virtual optokinetic system (VOS),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,virtual optokinetic system (VOS),performance test,all ages,No,,Visual acuity (n=20 mice per group) was assessed using the virtual optokinetic system (VOS) under photopic conditions,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: virtual optokinetic system (VOS)"
Cogstate,clinical_assessment_tools,PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Cogstate,performance test,all ages,No,,Performance tasks (Cogstate) and observer-reported functioning (BRIEF) were the primary outcomes...computerized assessment battery (Cogstate) targeting neurocognitive processes,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Cogstate"
Behavior Rating Inventory of Executive Function,clinical_assessment_tools,PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Behavior Rating Inventory of Executive Function,questionnaire,caregiver,No,,a consistent parent completed a questionnaire of executive functioning (Behavior Rating Inventory of Executive Function; BRIEF),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Behavior Rating Inventory of Executive Function"
Wood's lamp,clinical_assessment_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wood's lamp,other,all ages,Yes,,"A Wood's lamp, which makes CALMs more visible, was used for CALM counting in CALM1, but not in CALM2.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wood's lamp"
Wechsler Intelligence Scales,clinical_assessment_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scales,scale,pediatric,No,,We administered age-appropriate versions of the Wechsler Intelligence Scales to measure global cognitive ability,Publication title lacks NF-specific terms: Influences of RASopathies on Neuroanatomical Variation in Children.
Rotarod apparatus,clinical_assessment_tools,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rotarod apparatus,performance test,all ages,No,,Motor function and motor learning were evaluated by rotarod apparatus,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rotarod apparatus"
Distress Thermometer (DT),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Distress Thermometer (DT),scale,all ages,No,,The Distress Thermometer (DT) was designed as a brief screening tool to assess for distress in adult cancer patients...the adapted pediatric DT was used in this study for all ages.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Distress Thermometer (DT)"
Children's Depression Inventory (CDI-S),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Children's Depression Inventory (CDI-S),questionnaire,pediatric,No,10.0,"The CDI–S (Kovacs, 1992) is a 10-item self-report measure for depression in children, ages 7 to 17 years.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Children's Depression Inventory (CDI-S)"
Children's Depression Inventory Parent Version (CDI-P),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Children's Depression Inventory Parent Version (CDI-P),questionnaire,caregiver,No,,"The CDI Parent Version (CDI-P) is derived directly from the CDI, is scored identically and has similar psychometric properties...completed by caregivers of all patients, ages 7–21.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Children's Depression Inventory Parent Version (CDI-P)"
Lansky Score,clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lansky Score,scale,pediatric,No,,Medical providers completed a Lansky score for patients 17 years and younger...These scores indicate the disease severity and functional capabilities of the patient,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Lansky Score"
Karnofsky Score,clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Karnofsky Score,scale,adult,No,,a Karnofsky score for patients 18 years and older. These scores indicate the disease severity and functional capabilities of the patient...range from 0–100 in increments of 10,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Karnofsky Score"
Distress Thermometer Acceptability and Feasibility Scales,clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.8,Development,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Distress Thermometer Acceptability and Feasibility Scales,scale,all ages,Yes,,"Patients, primary caregivers, and the child's primary medical provider rated on a scale of 1–4 how easy or difficult the DT was to complete...The DT Acceptability and Feasibility Scales were developed by the study investigators","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Distress Thermometer Acceptability and Feasibility Scales"
Nottingham Health Profile,clinical_assessment_tools,PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nottingham Health Profile,questionnaire,adult,No,,"The comparator measure used in the UK was the Nottingham Health Profile (NHP; Hunt et al., 1981)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Nottingham Health Profile"
Short Form-36,clinical_assessment_tools,PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Short Form-36,questionnaire,adult,No,36.0,"the Short Form‐36 (SF‐36; Ware & Sherbourne, 1992) was used in the US","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Short Form-36"
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,clinical_assessment_tools,PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,scale,all ages,No,,Adverse events were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3"
Impact of Pediatric Illness (IPI) Scale,clinical_assessment_tools,PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Impact of Pediatric Illness (IPI) Scale,scale,pediatric,No,43.0,QOL was assessed using the Impact of Pediatric Illness (IPI) Scale for children 6–18 years of age,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Impact of Pediatric Illness (IPI) Scale"
STIR MRI,clinical_assessment_tools,PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,STIR MRI,biomarker assay,all ages,Yes,,STIR MRI of up to three clinically relevant index PN was performed for volumetric analysis,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: STIR MRI"
ImageJ 1.53a,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ 1.53a,Analysis Software,1.53a,,,,,,,,,,,,,,,"Images were acquired using Image Studio Lite Version 5.2 software, and LAS AF Lite 3.2.0 software and analyzed using ImageJ 1.53a software",Generic tool (versioned): ImageJ 1.53a
Prism7 (GraphPad),computational_tools,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism7 (GraphPad),Analysis Software,7,,,,,,,,,,,,,,,"Data statistical analyses were performed by unpaired two-tailed Student's t-test (Prism7, GraphPad)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
GraphPad Prism version 6.0h,computational_tools,PMID:32781282 | PMID:29847659,10.1016/j.trsl.2020.08.001 | 10.1167/iovs.17-22588,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 6.0h,Analysis Software,6.0h,,,,,,,,,,,,,,,"Analysis was performed using GraphPad Prism version 6.0h (La Jolla, CA, USA)",Generic tool (versioned): GraphPad Prism version 6.0h
"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",computational_tools,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",Analysis Software,1.48,,,,,,,,,,,,,,,"More than 200 cells were counted for each drug concentration using ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)","Generic tool (versioned): ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)"
ImageJ (v1.53a),computational_tools,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,ImageJ (v1.53a),Analysis Software,v1.53a,,,,,,,,,,,,,,,Fiber diameter and angle were measured using ImageJ (v1.53a) with at least 200 fibers per fiber type,Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
NIH ImageJ (version 1.53a),computational_tools,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,NIH ImageJ (version 1.53a),Analysis Software,version 1.53a,,,,,,,,,,,,,,,"The images were analyzed using NIH ImageJ (version 1.53a) software. Aspect ratio, which is the longest length of the cell divided by the shortest length",Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
"SAS, version 9.4",computational_tools,PMID:37378983 | PMID:31462295 | PMID:33507822 | PMID:32572180,10.1001/jamanetworkopen.2023.20599 | 10.1186/s40478-019-0792-5 | 10.1200/JCO.20.02220 | 10.1038/s41436-020-0873-7,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial. | Telomere alterations in neurofibromatosis type 1-associated solid tumors. | NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. | Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"SAS, version 9.4",Analysis Software,9.4,,,,,,,,,,,,,,,"We used SAS, version 9.4 (SAS Institute Inc), for analyses | Statistical analyses were performed using GraphPad Prism version 8.0 (San Diego, CA), SAS version 9.4 (Cary, NC) | The pain and QOL data were summarized with descriptive statistics (means, standard deviation [SD]) via SAS version 9.4 (Cary, NC). | Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.5.0","Generic tool (versioned): SAS, version 9.4"
FastQC (version 0.11.2),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,FastQC (version 0.11.2),Analysis Software,0.11.2,,,,,,,,,,,,,,,All sequencing datasets were evaluated using FastQC (version 0.11.2) to ensure high quality,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
Bowtie (version 1.0.0),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Bowtie (version 1.0.0),Analysis Software,1.0.0,,,,,,,,,,,,,,,We first built an index using all sgRNAs in each sample and then used Bowtie (version 1.0.0) to map the sgRNA sequences,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
BWA version 0.7.5,computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,BWA version 0.7.5,Analysis Software,0.7.5,,,,,,,,,,,,,,,We mapped the reads to the reference genomic sequence using BWA version 0.7.5 and SAMtools,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
SAMtools (version 0.1.19),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SAMtools (version 0.1.19),Analysis Software,0.1.19,,,,,,,,,,,,,,,We mapped the reads to the reference genomic sequence using BWA version 0.7.5 and SAMtools (version 0.1.19),Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
VarScan2 (version 2.3),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,VarScan2 (version 2.3),Analysis Software,2.3,,,,,,,,,,,,,,,We then used VarScan2 (version 2.3) to identify insertions and deletions with the 'pileup2indel' mode,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
STAR (version 2.3.0e),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,STAR (version 2.3.0e),Analysis Software,2.3.0e,,,,,,,,,,,,,,,We aligned RNA-seq reads to the mm10 genome using STAR (version 2.3.0e) with default parameters,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
DESeq (version 1.18.0),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,DESeq (version 1.18.0),Package/Library,1.18.0,,,,,,,,,,,,,,,We then determined differential expression using DESeq (version 1.18.0) and accounted for possible batch effects,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
GraphPad Prism 4.0,computational_tools,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism 4.0 software (GraphPad, La Jolla, CA)",Generic tool (versioned): GraphPad Prism 4.0
NextGENe software v.2.3.4.1,computational_tools,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,NextGENe software v.2.3.4.1,Analysis Software,v.2.3.4.1,,,,,,,,,,,,,,,"The data were analysed using NextGENe software v.2.3.4.1 (Softgenetics, PA, USA) with the default settings",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
g:Profiler,computational_tools,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,g:Profiler,Web Application,,,,,,,,,,,,,,,,GO analysis was performed using g:Profiler,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
BioVenn,computational_tools,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioVenn,Web Application,,,,,,,,,,,,,,,,Venn diagrams were generated using BioVenn,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
PathVisio software,computational_tools,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PathVisio software,Analysis Software,,,,,,,,,,,,,,,,Proximity maps were generated using PathVisio software,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
Graphpad Prism 6,computational_tools,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Graphpad Prism 6,Analysis Software,6,,,,,,,,,,,,,,,Statistical significance was determined by ANOVA followed by Bonferroni's posthoc test for multiple comparisons and student's t-test for two groups using Graphpad Prism 6 software,Generic tool (versioned): Graphpad Prism 6
Burrows–Wheeler Aligner,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Burrows–Wheeler Aligner,Analysis Software,0.7.8,,,,,,,,,,,,,,,Burrows–Wheeler Aligner (version 0.7.8) was utilized to map the paired-end clean reads,Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
control-FREEC,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,control-FREEC,Analysis Software,9.9,,,,,,,,,,,,,,,CNV is detected by control-FREEC (version 9.9),Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
RStudio,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,RStudio,Analysis Software,1.2.5033,,,,,,,,,,,,,,,We developed R codes and used RStudio (version 1.2.5033),Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
APE,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,APE,Package/Library,5.2,,,,,,,,,,,,,,,"R package ""Analyses of Phylogenetics and Evolution"" (APE, version 5.2)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
MEGAX,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MEGAX,Analysis Software,0.1,,,,,,,,,,,,,,,"MEGAX (version 0.1, for MAC) to generate SKY-based phylogenetic trees",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
Human Splicing Finder (HSF) Version 2.4.1,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Splicing Finder (HSF) Version 2.4.1,Web Application,2.4.1,,,,,,,,,,,,,,,Human Splicing Finder (HSF) Version 2.4.1 ( http://www.umd.be/HSF/ Assessing on 21 December 2020),Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Combined Annotation Dependent Depletion (CADD) v1.6,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Combined Annotation Dependent Depletion (CADD) v1.6,Web Application,v1.6,,,,,,,,,,,,,,,Combined Annotation Dependent Depletion (CADD) v1.6 ( https://cadd.gs.washington.edu/ Assessing on 21 December 2020),Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
ImageJ Cell Counter extension,computational_tools,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ Cell Counter extension,Plugin,,,,,,,,,,,,,,,,The target cell type was counted using the ImageJ Cell Counter extension (NIH),Generic tool (versioned): ImageJ Cell Counter extension
R version 3.5.1,computational_tools,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R version 3.5.1,Analysis Software,3.5.1,,,,,,,,,,,,,,,Statistical analysis was performed using GraphPad Prism 7 and R version 3.5.1.,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
R version 3.5.0,computational_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R version 3.5.0,Analysis Software,3.5.0,,,,,,,,,,,,,,,"Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.5.0",Generic tool (versioned): R version 3.5.0
"Image J1.45s, version 1.44p",computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"Image J1.45s, version 1.44p",Analysis Software,1.44p,,,,,,,,,,,,,,,"The width and equatorial length of the testes were measured on testicular histological images using Image J1.45s, version 1.44p (NIH, Bethesda, MD)","Generic tool (versioned): Image J1.45s, version 1.44p"
ImageJ (version 1.47),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (version 1.47),Analysis Software,1.47,,,,,,,,,,,,,,,AXL immunohistochemistry was analyzed using the IHC Profiler plugin for ImageJ (version 1.47),Generic tool (versioned): ImageJ (version 1.47)
GraphPad Prism V9,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism V9,Analysis Software,V9,,,,,,,,,,,,,,,All graphs and statistical analyses were performed using GraphPad Prism V9,Generic tool (versioned): GraphPad Prism V9
ImageJ (v.2.0.0),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (v.2.0.0),Analysis Software,v.2.0.0,,,,,,,,,,,,,,,Images were taken using a Zeiss Axio Imager M2 and quantified using ImageJ (v.2.0.0),Generic tool (versioned): ImageJ (v.2.0.0)
Affymetrix GeneChip Mouse Genome 430 2.0 Array,computational_tools,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Affymetrix GeneChip Mouse Genome 430 2.0 Array,Analysis Software,,,,,,,,,,,,,,,,"Mouse optic glioma neurospheres, Nf1−/− TVZ NSCs (TVZ_Cre) and wild-type TVZ NSCs (TVZ_LacZ) RNA was subjected to Affymetrix GeneChip Mouse Genome 430 2.0 Array hybridization",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
Partex Genomics Suite Version 6.6 beta,computational_tools,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Partex Genomics Suite Version 6.6 beta,Analysis Software,6.6 beta,,,,,,,,,,,,,,,the resulting data analyzed using Partex Genomics Suite Version 6.6 beta,Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
pheatmap package,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,pheatmap package,Package/Library,,http://cran.r-project.org/web/packages/pheatmap/index.html,,,,,,,,,,,,,,The heatmap was generated using CRAN's pheatmap package ( http://cran.r-project.org/web/packages/pheatmap/index.html ),"Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
CalcuSyn Version 2.1,computational_tools,PMID:24681606 | PMID:23535903,10.18632/oncotarget.1609 | 10.1158/2159-8290.CD-13-0081,"Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CalcuSyn Version 2.1,Analysis Software,2.1,,,,,,,,,,,,,,,"All data analysis was done using Calcusyn software (CalcuSyn Version 2.1, BioSoft)",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
GraphPad Prism version 5.0d,computational_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 5.0d,Analysis Software,5.0d,,,,,,,,,,,,,,,Analysis was performed using GraphPad Prism version 5.0d (GraphPad Software),Generic tool (versioned): GraphPad Prism version 5.0d
Origin® 8,computational_tools,PMID:35393510 | PMID:35614131,10.1038/s41418-022-00991-4 | 10.1038/s41418-022-01020-0,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Origin® 8,Analysis Software,8,,,,,,,,,,,,,,,"Statistical significance was determined using Origin® 8 (OriginLab, Northampton, MA) | Statistical significance was determined using Origin ® 8 (OriginLab, Northampton, MA)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
Prism 6.0,computational_tools,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism 6.0,Analysis Software,6.0,,,,,,,,,,,,,,,Protein quantification and assessment of significance was determined in Prism 6.0,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
Feature extractionTM software,computational_tools,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Feature extractionTM software,Analysis Software,9.5.1.1,,,,,,,,,,,,,,,"microarray images were automatically analysed using Feature extractionTM software, version 9.5.1.1 (Agilent Technologies)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
Filtlong v0.2.0,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Filtlong v0.2.0,Command-line Tool,v0.2.0,https://github.com/rrwick/Filtlong,,,,,,,,,,,,,,ONT reads meeting a minimum Q-value of 10 were size- and chimera-filtered with Filtlong v0.2.0,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Porechop v0.2.4,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Porechop v0.2.4,Command-line Tool,v0.2.4,https://github.com/rrwick/Porechop,,,,,,,,,,,,,,ONT reads meeting a minimum Q-value of 10 were size- and chimera-filtered with Filtlong v0.2.0 and Porechop v0.2.4,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Flye v2.5,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Flye v2.5,Analysis Software,v2.5,,,,,,,,,,,,,,,"Filtered reads were assembled with Flye v2.5, enforcing a 10,000 bp overlap minimum","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
GCpp v1.0.0-1807624,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GCpp v1.0.0-1807624,Analysis Software,v1.0.0-1807624,https://github.com/PacificBiosciences/gcpp,,,,,,,,,,,,,,Approximately 20× PacBio subread coverage was used with GCpp v1.0.0-1807624 to independently error-correct the ONT-based Flye assembly,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
purge_haplotigs,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,purge_haplotigs,Command-line Tool,,https://bitbucket.org/mroachawri/purge_haplotigs/src/master/,,,,,,,,,,,,,,The resulting error-corrected haploid assembly was deduplicated with purge_haplotigs commit be7e44b,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Juicer v1.6.2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Juicer v1.6.2,Analysis Software,v1.6.2,https://github.com/aidenlab/juicer,,,,,,,,,,,,,,"Juicer v1.6.2 and 3D-DNA v180114 were used to scaffold the deduplicated, error-corrected assembly with the Hi-C data","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
3D-DNA v180114,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,3D-DNA v180114,Analysis Software,v180114,https://github.com/aidenlab/3d-dna,,,,,,,,,,,,,,"Juicer v1.6.2 and 3D-DNA v180114 were used to scaffold the deduplicated, error-corrected assembly with the Hi-C data","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
BUSCO v5.7.0,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BUSCO v5.7.0,Analysis Software,v5.7.0,https://busco.ezlab.org/,,,,,,,,,,,,,,We assessed the quality of our genome assembly using BUSCO v5.7.0 with mammalia_odb10,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
QUASTv5.0.2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,QUASTv5.0.2,Analysis Software,v5.0.2,https://quast.sourceforge.net/,,,,,,,,,,,,,,We assessed the quality of our genome assembly using BUSCO v5.7.0 with mammalia_odb10 and QUASTv5.0.2,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Liftoff v1.6.3,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Liftoff v1.6.3,Analysis Software,v1.6.3,https://github.com/agshumate/Liftoff,,,,,,,,,,,,,,Putative genes in the WMSTM draft genome were identified using Liftoff v1.6.3 with default parameters,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
SnapGeneTM Version 7.2.1,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SnapGeneTM Version 7.2.1,Analysis Software,7.2.1,,,,,,,,,,,,,,,aligned it to the S. scrofa reference coding sequence using the align sequences feature in SnapGeneTM Version 7.2.1,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
PyMOL Version 3.0.5,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PyMOL Version 3.0.5,Analysis Software,3.0.5,,,,,,,,,,,,,,,"The structural predictions from WMSTM and human proteins were aligned using PyMOL (The PyMOL Molecular Graphics System, Version 3.0.5 Schrödinger, LLC.)","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Skewer v0.2.2.b,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Skewer v0.2.2.b,Command-line Tool,v0.2.2.b,,,,,,,,,,,,,,,"Adapters, low-quality bases, and primers were trimmed from reads to obtain a Phred score of 20 via the trimming software Skewer (v0.2.2.b)","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Tassel pipeline version 2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Tassel pipeline version 2,Pipeline,version 2,,,,,,,,,,,,,,,The Tassel pipeline (version 2) was used to process sequence reads to single nucleotide polymorphism (SNP) genotypes,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
VCFtools v.0.1.16,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VCFtools v.0.1.16,Command-line Tool,v.0.1.16,,,,,,,,,,,,,,,The population-wide inbreeding coefficient F was calculated with VCFtools (v.0.1.16),"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Beagle v4.1,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Beagle v4.1,Analysis Software,v4.1,,,,,,,,,,,,,,,Beagle v4.1 was used to perform whole genome phasing and to impute missing data,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
itol v6.9.1,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,itol v6.9.1,Web Application,v6.9.1,https://itol.embl.de/,,,,,,,,,,,,,,A mid-point rooted topology was created from the VCF data using RAxML and visualized with itol v6.9.1,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
GENIE (Genomics Evidence Neoplasia Information Exchange),computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GENIE (Genomics Evidence Neoplasia Information Exchange),Database,v.7.0,,,,,,,,,,,,,,,cancer genomics databases including GENIE (Genomics Evidence Neoplasia Information Exchange),Publication title lacks NF-specific terms: Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
TCGA (The Cancer Genome Atlas),computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TCGA (The Cancer Genome Atlas),Database,,,,,,,,,,,,,,,,databases in cBioPortal including TCGA (The Cancer Genome Atlas),Publication title lacks NF-specific terms: Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
"ImageJ software v.1.49 (NIH, USA)",computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"ImageJ software v.1.49 (NIH, USA)",Analysis Software,v.1.49,,,,,,,,,,,,,,,"...Images were analyzed using ImageJ software v.1.49 (NIH, USA), and the percentage of stained area in each picture was obtained...","Generic tool (versioned): ImageJ software v.1.49 (NIH, USA)"
Karyostudio 1.3 software,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Karyostudio 1.3 software,Analysis Software,1.3,,,,,,,,,,,,,,,The analysis was performed using the Karyostudio 1.3 software (Illumina),Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Partek Flow software,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Partek Flow software,Analysis Software,v10.0,,,,,,,,,,,,,,,"RNA sequencing analysis was generated using Partek Flow software, v10.0",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Imaris software,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Imaris software,Analysis Software,9,,,,,,,,,,,,,,,"Images were 3D-rendered using Imaris software (Imaris 9, Oxford Instruments, Abingdon, UK)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
SPSS 25,computational_tools,PMID:34646065,10.1155/2021/9386823,Survival and ,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS 25,Analysis Software,25,,,,,,,,,,,,,,,"All data were analyzed using statistical software (SPSS 25, IBM Co. Armonk, NY)",Publication title lacks NF-specific terms: Survival and
R version 1.2,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R version 1.2,Analysis Software,1.2,,,,,,,,,,,,,,,Statistical analyses were performed in SPSS version25 and R version 1.2,Generic tool (versioned): R version 1.2
Python version 3.10,computational_tools,PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Python version 3.10,Analysis Software,3.10,,,,,,,,,,,,,,,"All statistics and models were conducted in Python version 3.10 (Python Software Foundation, Wilmington, Delaware, US).",Generic tool (versioned): Python version 3.10
ImageJ 1.54g software,computational_tools,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ 1.54g software,Analysis Software,1.54g,,,,,,,,,,,,,,,"Fluorescence intensity of P-glycoprotein was quantified using ImageJ 1.54g software (National Institutes of Health, Bethesda, MD, USA).",Generic tool (versioned): ImageJ 1.54g software
PhenoCapture 3.3,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,PhenoCapture 3.3,Analysis Software,3.3,,,,,,,,,,,,,,,Images were captured every 15 min using a time-lapse image software (PhenoCapture 3.3),Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Fiji 2.0,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Fiji 2.0,Analysis Software,2.0,,,,,,,,,,,,,,,Images were captured every 15 min using a time-lapse image software (PhenoCapture 3.3) and analyzed using Fiji 2.0,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
GraphPad Prism Version 6,computational_tools,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism Version 6,Analysis Software,6,,,,,,,,,,,,,,,"The IC50 was calculated using GraphPad Prism Version 6 (La Jolla, CA).",Generic tool (versioned): GraphPad Prism Version 6
GraphPad Prism version 8.0.1,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism version 8.0.1,Analysis Software,8.0.1,,,,,,,,,,,,,,,"The significance of differences was evaluated either by one-way ANOVA, followed by Tukey's post hoc test to correct for multiple comparisons, or by Student's t-test for two groups using GraphPad Prism version 8.0.1",Generic tool (versioned): GraphPad Prism version 8.0.1
Image J software,computational_tools,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image J software,Analysis Software,,,,,,,,,,,,,,,,"surface area of the tumor on each sequential image was determined using the measurement tool on Image J software (NIH, Bethesda, MD)",Generic tool (versioned): Image J software
GraphPad Prism 6.0,computational_tools,PMID:26219339 | PMID:31527226,10.18632/oncotarget.4858 | 10.1158/1535-7163.MCT-19-0123,"A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 6.0,Analysis Software,6.0,,,,,,,,,,,,,,,"Growth curves were plotted using GraphPad Prism 6.0 software (San Diego, CA) | GraphPad Prism 5.0 and 6.0 was used to perform all statistical analyses. Comparison of the means for nerve root volume, tumor number, KI-67 proliferation index",Generic tool (versioned): GraphPad Prism 6.0
R version 3.2.3,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R version 3.2.3,Analysis Software,3.2.3,,,,,,,,,,,,,,,We performed all preprocessing steps using R version 3.2.3,Generic tool (versioned): R version 3.2.3
PERADIGM,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.95,Development,True,0.67,Medium,,,,,,,,,,,,,,,PERADIGM,Analysis Software,,,,,,,,,,,,,,,,"Here, we introduce PERADIGM ( Phenotype Embedding similarity-based RAre DIsease Gene Mapping), a novel framework that leverages natural language processing techniques",Publication title lacks NF-specific terms: PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.
Word2Vec,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Word2Vec,Package/Library,,,,,,,,,,,,,,,,We employed the Word2Vec embedding model to obtain static embedding vectors for the phenotypes,Publication title lacks NF-specific terms: PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.
bam-readcount,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bam-readcount,Analysis Software,,,,,,,,,,,,,,,,bam-readcount was then used to compute additional quality parameters,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
regioneR,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,regioneR,Package/Library,,,,,,,,,,,,,,,,Variants were filtered using the regioneR bioconductor package,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
CLC Genomics Workbench v6,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CLC Genomics Workbench v6,Analysis Software,v6,,,,,,,,,,,,,,,CLC Genomics Workbench v6 (Qiagen) was used to analyze data from I2HCP V1,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
GraphPad Prism version 5.01,computational_tools,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 5.01,Analysis Software,5.01,,,,,,,,,,,,,,,"AUCs were compared with two-way ANOVA followed by Bonferroni post-tests, using GraphPad Prism version 5.01","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
STATA 11,computational_tools,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STATA 11,Analysis Software,11,,,,,,,,,,,,,,,"distributions were first checked for normality by using the Shapiro–Wilk's test with STATA 11 (StataCorp, College Station, TX)","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
Schrödinger software suite release 2017–1,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Schrödinger software suite release 2017–1,Analysis Software,2017-1,,,,,,,,,,,,,,,"Briefly, the Schrödinger software suite release 2017–1 was used for system setup.",Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
AMBER16,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,AMBER16,Analysis Software,16,,,,,,,,,,,,,,,Equilibration and production steps were performed using the AMBER16 MD engine,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
VMD (version 1.9.3),computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VMD (version 1.9.3),Analysis Software,1.9.3,,,,,,,,,,,,,,,Descriptors were generated with in-house scripts using VMD (version 1.9.3) to calculate solvent accessible surface area,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
gromacs (version 4.6),computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gromacs (version 4.6),Analysis Software,4.6,,,,,,,,,,,,,,,g_mindist tool of gromacs (version 4.6) to get residue–residue contacts,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
MATLAB version 2019b,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB version 2019b,Analysis Software,2019b,,,,,,,,,,,,,,,The predictive power of the trained models was internally checked via 5-fold cross validation procedure available in MATLAB version 2019b,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
SPSS version 19.0,computational_tools,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS version 19.0,Analysis Software,19.0,,,,,,,,,,,,,,,"The statistical analyses were undertaken using a licensed version of SPSS (version 19.0, SPSS Inc, Chicago, IL, USA) compatible with Windows",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
Ethovision 11,computational_tools,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Ethovision 11,Analysis Software,11,,,,,,,,,,,,,,,"Locomotor activity was analyzed using Ethovision 11 software (Noldus Information Technology, Wageningen, The Netherlands)",Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
ARACNe-AP algorithm,computational_tools,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ARACNe-AP algorithm,Analysis Software,,,,,,,,,,,,,,,,the network was built using the ARACNe-AP algorithm. The ARACNe-AP algorithm reconstructs gene regulatory networks from large-scale gene expression data,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
DESeq2 version 1.18.1,computational_tools,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2 version 1.18.1,Package/Library,1.18.1,,,,,,,,,,,,,,,The differential expression and fold change calculations on the RNA-Seq datasets were performed using the R package DESeq2 version 1.18.1,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
ichorCNA,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ichorCNA,Analysis Software,v.0.2.0,,,,,,,,,,,,,,,copy-number–based estimation of tumor fraction were then performed using the ichorCNA tool (Broad v.0.2.0),Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
Python sklearn,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Python sklearn,Package/Library,v.1.3.2,,,,,,,,,,,,,,,We then used the Python sklearn library (v.1.3.2) decomposition module incorporating up to 20 components,Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
XF24 Extracellular Flux Analyzer,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,XF24 Extracellular Flux Analyzer,Analysis Software,,,,,,,,,,,,,,,,"OCR was assessed in real-time with the XF24 Extracellular Flux Analyzer (Agilent, North Billerica, MA, USA)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
LC-MS/MS (Quattro Premier),computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LC-MS/MS (Quattro Premier),Analysis Software,,,,,,,,,,,,,,,,"Mass spectrometry analysis was carried out with an LC-MS/MS (Quattro Premier interfaced with an Acquity UPLC system, Waters)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
FACSCanto II flow cytometer,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSCanto II flow cytometer,Analysis Software,,,,,,,,,,,,,,,,"Samples were analyzed on a FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
FACSDiva software,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSDiva software,Analysis Software,,,,,,,,,,,,,,,,Data acquisition and analysis were performed using FACSDiva software,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
GAMESS software,computational_tools,PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GAMESS software,Analysis Software,,,,,,,,,,,,,,,,Quantum mechanics/molecular mechanics (QM/MM) computations...were performed using the General Atomic and Molecular Electronic Structure System (GAMESS software),Publication title lacks NF-specific terms: Spectrophotometric and computational characterization of charge transfer complex
Mutiwfn 3.7,computational_tools,PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mutiwfn 3.7,Analysis Software,3.7,,,,,,,,,,,,,,,"Mutiwfn 3.7, VMD, and the GAMESS-optimized SEL-DDQ complex were used in the hirshfeld surface HS study",Publication title lacks NF-specific terms: Spectrophotometric and computational characterization of charge transfer complex
GraphPad Prism 5.0,computational_tools,PMID:31527226 | PMID:24817309,10.1158/1535-7163.MCT-19-0123 | 10.1371/journal.pone.0097320,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 5.0,Analysis Software,5.0,,,,,,,,,,,,,,,"GraphPad Prism 5.0 and 6.0 was used to perform all statistical analyses. Comparison of the means for nerve root volume, tumor number, KI-67 proliferation index | Statistical significance (p<0.05) was determined using the appropriate test as described in figure legends using GraphPad Prism 5.0 software",Generic tool (versioned): GraphPad Prism 5.0
FastQC (RRID:SCR_014583),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,FastQC (RRID:SCR_014583),Analysis Software,,https://www.bioinformatics.babraham.ac.uk/projects/fastqc/,,,,,,,,,,,,,,All resulting FASTQ files passed quality control by FastQC (RRID:SCR_014583; https://www.bioinformatics.babraham.ac.uk/projects/fastqc/),Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
TrimGalore (RRID:SCR_011847),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,TrimGalore (RRID:SCR_011847),Analysis Software,0.4.5,https://www.bioinformatics.babraham.ac.uk/projects/trim_galore,,,,,,,,,,,,,,"RNA sequencing reads were 3′ trimmed for base quality 15 and adapter sequences using version 0.4.5 of TrimGalore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore, RRID:SCR_011847)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
STAR v2.6 (RRID:SCR_004463),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,STAR v2.6 (RRID:SCR_004463),Analysis Software,v2.6,,,,,,,,,,,,,,,and then aligned to human genome assembly hg19 with STAR v2.6 (RRID:SCR_004463) using default parameters,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
HTSeq v0.9.1 (RRID:SCR_005514),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,HTSeq v0.9.1 (RRID:SCR_005514),Analysis Software,v0.9.1,,,,,,,,,,,,,,,Read count tables were generated with HTSeq v0.9.1 (RRID:SCR_005514),Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
deepTools v3.1 (RRID:SCR_016366),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,deepTools v3.1 (RRID:SCR_016366),Analysis Software,v3.1,,,,,,,,,,,,,,,These library size factors were also used with deepTools v3.1 (RRID:SCR_016366) to create normalized bigwigs using bamCoverage,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
Homer v4.5 (RRID:SCR_010881),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Homer v4.5 (RRID:SCR_010881),Analysis Software,v4.5,http://homer.ucsd.edu,,,,,,,,,,,,,,"Pathway enrichment (gene sets and GO) was performed on each cluster using Homer v4.5 (http://homer.ucsd.edu, RRID:SCR_010881)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"featureCounts (v1.5.0-p1, RRID:SCR_012919)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"featureCounts (v1.5.0-p1, RRID:SCR_012919)",Analysis Software,v1.5.0-p1,,,,,,,,,,,,,,,"and used featureCounts (v1.5.0-p1, RRID:SCR_012919; ref. 79) to count RNA-seq fragments mapped to them",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"pheatmap (v.1.0.12, RRID:SCR_016418)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"pheatmap (v.1.0.12, RRID:SCR_016418)",Package/Library,v.1.0.12,,,,,,,,,,,,,,,"were subject to k-means clustering via pheatmap (v.1.0.12, RRID:SCR_016418), separately for the three classes of REs",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"Partek Genomics Suite (v 7.0, RRID:SCR_011860)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"Partek Genomics Suite (v 7.0, RRID:SCR_011860)",Analysis Software,v 7.0,,,,,,,,,,,,,,,"PCA of methylation data at all tiles (regions) was generated in Partek Genomics Suite (v 7.0, RRID:SCR_011860)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",Analysis Software,7 Research Edition,,,,,,,,,,,,,,,"All data were processed and analyzed with FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
ExplorDTI,computational_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ExplorDTI,Analysis Software,,,,,,,,,,,,,,,,Diffusion-weighted images were preprocessed using ExplorDTI (68),Publication title lacks NF-specific terms: Brain-wide structural and functional disruption in mice with oligodendrocyte-spe
Advanced Normalization Tools (ANTs),computational_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Advanced Normalization Tools (ANTs),Analysis Software,,,,,,,,,,,,,,,,"template, B0, for both controls and Plp-Nf1 fl/+ animals was created using Advanced Normalization Tools (ANTs) (70)",Publication title lacks NF-specific terms: Brain-wide structural and functional disruption in mice with oligodendrocyte-spe
GraphPad Prism software v7,computational_tools,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism software v7,Analysis Software,v7,,,,,,,,,,,,,,,Statistical analysis was carried out using GraphPad Prism software v7,Generic tool (versioned): GraphPad Prism software v7
CRISPRscan,computational_tools,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CRISPRscan,Web Application,,https://www.crisprscan.org/,,,,,,,,,,,,,,CRISPRscan (https://www.crisprscan.org/) was used to identify gRNA target sequences in exon 1 of the tgfb3 gene,Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
MATLAB software,computational_tools,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MATLAB software,Analysis Software,R2019a,,,,,,,,,,,,,,,"Electronic image files were processed using MATLAB software (MathWorks Inc., R2019a, USA)",Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
GraphPad Prism version 8.0,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 8.0,Analysis Software,8.0,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism version 8.0 (San Diego, CA)",Generic tool (versioned): GraphPad Prism version 8.0
R version 3.3.2,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R version 3.3.2,Analysis Software,3.3.2,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism version 8.0 (San Diego, CA), SAS version 9.4 (Cary, NC), and R version 3.3.2",Generic tool (versioned): R version 3.3.2
melodic v3.15,computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,melodic v3.15,Analysis Software,v3.15,,,,,,,,,,,,,,,we ran group-based ICA using melodic v3.15,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
fMRI Expert Analysis Tool (FEAT),computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,fMRI Expert Analysis Tool (FEAT),Analysis Software,,,,,,,,,,,,,,,,We used fMRI Expert Analysis Tool (FEAT) to model extracted time series,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
Multiple Imputation by Chained Equations (MICE),computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Multiple Imputation by Chained Equations (MICE),Package/Library,,,,,,,,,,,,,,,,using a predictive mean matching for mixed types and the Multiple Imputation by Chained Equations (MICE) package in R,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
GEOquery,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GEOquery,Package/Library,,,,,,,,,,,,,,,,Expression matrices and corresponding phenotype metadata were processed using the GEOquery and Biobase R packages,Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
Biobase,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Biobase,Package/Library,,,,,,,,,,,,,,,,Expression matrices and corresponding phenotype metadata were processed using the GEOquery and Biobase R packages,Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
Burrows-Wheeler Aligner (bwa-0.7.15),computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Burrows-Wheeler Aligner (bwa-0.7.15),Command-line Tool,0.7.15,,,,,,,,,,,,,,,FASTQ files were first aligned to the human reference genome (hg19) by the Burrows-Wheeler Aligner (bwa-0.7.15),Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
Sambamba (v0.6.6),computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Sambamba (v0.6.6),Command-line Tool,v0.6.6,https://github.com/biod/sambamba,,,,,,,,,,,,,,PCR duplications that cause bias in copy-number analysis were filtered out using Sambamba (v0.6.6),Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
CASAVA v1.82,computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,CASAVA v1.82,Analysis Software,v1.82,,,,,,,,,,,,,,,Raw image files were processed using CASAVA v1.82 for base calling and generating the raw sequencing data.,Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
FreeSurfer,computational_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FreeSurfer,Analysis Software,"5.3, 7.2.0",,,,,,,,,,,,,,,the data were processed using Freesurfer (https://surfer.nmr.mgh.harvard.edu version 5.3)...processed using Freesurfer (version 7.2.0),Publication title lacks NF-specific terms: Influences of RASopathies on Neuroanatomical Variation in Children.
FACSDiva v6.1,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FACSDiva v6.1,Analysis Software,v6.1,,,,,,,,,,,,,,,FACSDiva v6.1 and FlowJo software v10.0.8 (BD Biosciences) were used to collect and analyze data,Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
FlowJo software v10.0.8,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo software v10.0.8,Analysis Software,v10.0.8,,,,,,,,,,,,,,,FACSDiva v6.1 and FlowJo software v10.0.8 (BD Biosciences) were used to collect and analyze data,Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
GraphPad Prism v8.3,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism v8.3,Analysis Software,v8.3,,,,,,,,,,,,,,,The IC50s for each of the cell lines were determined using GraphPad Prism v8.3 (nonlinear regression and dose–response curve fitting),Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
HALO image analysis software v3.2,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HALO image analysis software v3.2,Analysis Software,v3.2,,,,,,,,,,,,,,,Tissues were scored for extent and intensity of staining using the HALO image analysis software v3.2,Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
ZEN imaging software v2.3,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ZEN imaging software v2.3,Analysis Software,v2.3,,,,,,,,,,,,,,,"Image acquisition was performed using a Zeiss LSM 880 with Airyscan confocal microscope (Zeiss, Oberkochen, Germany) and analyses performed with ZEN imaging software v2.3",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
ImageJ 1.46,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ 1.46,Analysis Software,1.46,,,,,,,,,,,,,,,images of calyx terminals were binary thresholded using the built-in thresholding function of ImageJ 1.46 (isodata algorithm),Generic tool (versioned): ImageJ 1.46
STRING version 11.5,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING version 11.5,Web Application,11.5,https://string-db.org/,,,,,,,,,,,,,,protein–protein interaction analysis using STRING version 11.5,Generic tool (versioned): STRING version 11.5
GraphPad Prism version 9,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 9,Analysis Software,9,,,,,,,,,,,,,,,The analysis was performed using GraphPad Prism version 9,Generic tool (versioned): GraphPad Prism version 9
UpSetR Version 1.4.0,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,UpSetR Version 1.4.0,Package/Library,1.4.0,,,,,,,,,,,,,,,Visualization of intersecting sets was performed with UpSetR Version 1.4.0 (R package).,Generic tool (versioned): UpSetR Version 1.4.0
ImageJ (v1.48),computational_tools,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (v1.48),Analysis Software,v1.48,,,,,,,,,,,,,,,The volume of tumour spheroids was measured using ImageJ (v1.48) software,Generic tool (versioned): ImageJ (v1.48)
XF96 Extracellular Flux Analyzer (Agilent Technologies),computational_tools,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,XF96 Extracellular Flux Analyzer (Agilent Technologies),Analysis Software,,,,,,,,,,,,,,,,Oxygen consumption rate (OCR) was measured in schwannoma and normal Schwann cells 24 h post protein delivery using an XF96 Extracellular Flux Analyzer,Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Gateway entry vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gateway entry vector,Plasmid,,,,,,,,,,,,,,,,,,,,PCR amplicons were cloned into pDonr255 and fully sequence-verified,Generic reagent name (no specific identifier): Gateway entry vector
baculovirus expression vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,baculovirus expression vector,Plasmid,pFastBac1,,,,,,,,,,,,,,,,,,,Gateway LR recombination was used to generate final expression clones in baculovirus Destination vectors pDest-635 (pFastBac1 with N-terminal His 6 tag) | pDest-636 (pFastBac1 with N-terminal His 6 -MBP tag),Generic reagent name (no specific identifier): baculovirus expression vector
E. coli expression vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,E. coli expression vector,Plasmid,,,,,,,,,,,,,,,,,,,,"E. coli Destination vector pDest-566 (N-terminal His6-MBP tag, Addgene catalog no. 11517)",Generic reagent name (no specific identifier): E. coli expression vector
Cas9/sgRNA,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9/sgRNA,Plasmid,pX330,,,,,,,,,,,,,,,,,,,sgRNA oligos (IDT) were annealed and cloned into the pX330 vector (addgene 42230),Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
Myc,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Myc,Plasmid,pT3,EF1α,,,,,,,,,,,,,,,,,,"pX330.sgNf1 (20 μg), pT3-EF1α-Myc (5 μg), and CMV-SB10 transposase (1 μg) plasmids were delivered",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
SB10 transposase,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SB10 transposase,Plasmid,,CMV,,,,,,,,,,,,,,,,,,"pX330.sgNf1 (20 μg), pT3-EF1α-Myc (5 μg), and CMV-SB10 transposase (1 μg) plasmids were delivered",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
pan-T-cell isolation,genetic_reagents,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,pan-T-cell isolation,,,,,,,,,,,,,,,,,,,,,"CD3+ T cells were purified from the lymph nodes using pan-T-cell isolation kit (Miltenyi Biotec, Auburn, CA)",Generic reagent name (no specific identifier): pan-T-cell isolation
RASopathy gene panel,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RASopathy gene panel,Other,,,,,,,,,,,,,,,,,,,,"Target sequencing was performed using the Haloplex custom target enrichment system (Agilent Technologies, CA, USA) on the MiSeq sequencing platform",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
Luciferase reporter,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Luciferase reporter,Plasmid,,Gal4,,,,,,,,,,,,,,,,,,"We introduced pGal-LUC (Clontech), pGal-ELK1 and the expression plasmids into HEK-293T cells",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
ELK1,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ELK1,Plasmid,,Gal4,,,,,,,,,,,,,,,,,,"We introduced pGal-LUC (Clontech), pGal-ELK1 and the expression plasmids into HEK-293T cells",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
Dual luciferase reporter,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Dual luciferase reporter,Other,,,,,,,,,,,,,,,,,,,,"The luciferase activity was measured using a Dual-Luciferase® Reporter assay system (Promega, WI, USA)",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
Renilla luciferase,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Renilla luciferase,Plasmid,,SV40,,,,,,,,,,,,,,,,,,"Transfection efficiencies were normalised to the control plasmid, which was pSV-RLuc (Promega, WI, USA) expressing Renilla luciferase",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
GFP fusion vector,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP fusion vector,Plasmid,pCMV6-AC-GFP,CMV,,,,,,,,,,,,,,,,,,"the in-frame coding sequence of RAF1, A2ML1 and RIT1 were subcloned into the pCMV6-AC-GFP vector such that the GFP coding sequence was fused in-frame",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
cmlc1 probe,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cmlc1 probe,Other,,,,,,,,,,,,,,,,,,,,"PFA fixed embryos were probed with digoxigenin-labelled cmlc1, which is a cardiac development marker for zebrafish, by in situ hybridization",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
mApple,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mApple,Plasmid,,,,,,,,,,,,,,,,,,,,mApple-N1 (Addgene plasmid no. 54567) was a gift from M. Davidson,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
ZO-1,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZO-1,Plasmid,,,,,,,,,,,,,,,,,,,,pSK ZO-1 (Addgene plasmid no. 30316) was a gift from J. Anderson and A. Fanning,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
GFP-NMHC II-B,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP-NMHC II-B,Plasmid,,CMV,,,,,,,,,,,,,,,,,,CMV-GFP-NMHC II-B (Addgene plasmid no. 11348) was a gift from R. Adelstein,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
GFP-vinculin,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP-vinculin,Plasmid,,,,,,,,,,,,,,,,,,,,pGFP(C3)-vinculin (Addgene plasmid no. 30312) was a gift from K. Hahn,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
venus-Scrib,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,venus-Scrib,Plasmid,,,,,,,,,,,,,,,,,,,,pKvenus-Scrib (Addgene plasmid no. 58738) was a gift from I. Macara,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
EGFP-hYAP1,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EGFP-hYAP1,Plasmid,,,,,,,,,,,,,,,,,,,,"pEGFP-C3-hYAP1 and pEGFP C3-Lats1 (Addgene plasmid nos. 19053 and 17843, respectively) were gifts from M. Sudol",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
EGFP-Lats1,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EGFP-Lats1,Plasmid,,,,,,,,,,,,,,,,,,,,"pEGFP-C3-hYAP1 and pEGFP C3-Lats1 (Addgene plasmid nos. 19053 and 17843, respectively) were gifts from M. Sudol",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
HA-AMOT p130,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HA-AMOT p130,Plasmid,,,,,,,,,,,,,,,,,,,,HA-AMOT p130 (Addgene plasmid no. 32821) was a gift from K. Guan,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
NLuc,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NLuc,Plasmid,pcDNA3.1,,,,,,,,,,,,,,,,,,,pcDNA3.1-ccdB-NLuc (Addgene plasmid no. 87067) was a gift from M. Taipale,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
4XBS2WT-Luc,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,4XBS2WT-Luc,Plasmid,,,,,,,,,,,,,,,,,,,,p4XBS2WT-Luc (Addgene plasmid no. 16593) was a gift from B. Vogelstein,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
8xGTIIC-luciferase,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,8xGTIIC-luciferase,Plasmid,,,,,,,,,,,,,,,,,,,,p8xGTIIC-luciferase (Addgene plasmid no. 34615) was a gift from S. Piccolo,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
p53 WT,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,p53 WT,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3 p53 WT (Addgene plasmid no. 69003) was a gift from D. Meek,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
ZsGreen,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZsGreen,Plasmid,pTRE3G-BI,,,,,,,,,,,,,,,,,,,"The Tet-inducible plasmids, pTRE3G-BI-ZsGreen and pCMV-Tet3G, were purchased from Tanaka Holdings",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
Tet3G,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet3G,Plasmid,,CMV,,,,,,,,,,,,,,,,,,"The Tet-inducible plasmids, pTRE3G-BI-ZsGreen and pCMV-Tet3G, were purchased from Tanaka Holdings",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
Trp53,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Trp53,Other,,,,,,,,,,,,,,,,,,,,"Trp53 Exon 3, F AAGTCACAGCACATGACGG",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Brca1,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Brca1,Other,,,,,,,,,,,,,,,,,,,,"Brca1 Exon 6, F GCGTCGATCATCCAGAGCGT",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Pten,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Pten,Other,,,,,,,,,,,,,,,,,,,,"Pten Exon 6, R ATATACATAGCGCCTCTGAC",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Haloplex HS,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Haloplex HS,Other,,,,,,,,,,,,,,,,,,,,"library preparation with a Haloplex HS or SureSelect kits (Agilent Technologies, Santa Clara, CA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
SALSA MLPA P081/P082,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SALSA MLPA P081/P082,Other,,,,,,,,,,,,,,,,,,,,"using the SALSA MLPA kits P081/P082 (MRC Holland, Amsterdam, The Netherlands)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Gentra Puregene,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gentra Puregene,Other,,,,,,,,,,,,,,,,,,,,"using the Gentra Puregene kit (Puregene Cell and Tissue kit plus Qiagen GmbH, Hilden, Germany)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
beta-globin,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,beta-globin,Plasmid,,,,,,,,,,,,,,,,,,,,"cloned into the beta-globin vector, as previously described",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Lipofectamine 2000,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine 2000,Other,,,,,,,,,,,,,,,,,,,,"transfected with 1 µg of the wild type or the mutated minigene using Lipofectamine 2000 (ThermoFisher Scientific, Watham, MA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
TOPO TA,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TOPO TA,Plasmid,,,,,,,,,,,,,,,,,,,,"purified bands were subcloned using the TOPO TA Cloning kit (ThermoFisher Scientific, Watham, MA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
dll4,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dll4,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
dlb,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dlb,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish | we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
hey1,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,hey1,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish | A 3kb region upstream of the hey1 gene's transcription start site was amplified by PCR and cloned into Xho1/Kpn1 sites of the pXP1 plasmid to create 3kb-hey1:luciferase",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
id2b,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,id2b,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish | we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
dll4-gRNAs,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dll4-gRNAs,,,u6,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
n3-gRNAs,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,n3-gRNAs,,,u6,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
n3,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,n3,,pCS2,,,,,,,,,,,,,,,,,,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
NF1-area probes,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1-area probes,Other,,,,,,,,,,,,,,,,,,,,"The deletions analyzed in this study were identified by MLPA analysis (P122-C1 NF1-area kit, MRC-Holland, The Netherlands)",Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
GenomeWalker adaptors,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GenomeWalker adaptors,Other,,,,,,,,,,,,,,,,,,,,"To perform GenomeWalker™ analysis (Clontech, Saint-Germain-en-Laye, France), genomic DNA (2.5 μg per experiment) was restriction digested",Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
NeoTkp,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NeoTkp,,,,,,,,,,,,,,,,,,,,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
NF31a,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NF31a,,,,,,,,,,,,,,,,,,,,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
NF31b,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NF31b,,,,,,,,,,,,,,,,,,,,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
2.5S NGF,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,2.5S NGF,,,,,,,,,,,,,,,,,,,,,"50 ng/ml nerve growth factor [2.5S NGF, Harlan Bio-products]",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
rhGGF2,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,rhGGF2,,,,,,,,,,,,,,,,,,,,,"amplified for 1 week in recombinant human glial growth factor (rhGGF2, Cambridge Neuroscience)",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
Abcg1,genetic_reagents,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Abcg1,Plasmid,pLKO.1,,,,,,,,,,,,,,,,,,,"Abcg1 shRNA or control shGFP-containing pLKO.1 plasmid was co-transfected with pMDLg/pRRE, pRSV-REV and pCMV-VSV-G",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
GSK3B,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GSK3B,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems | GSK3B and Luciferase cDNA (Invitrogen) were each cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
AXIN1,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AXIN1,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
CTNNB1,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CTNNB1,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
TNKS,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TNKS,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
RSPO2,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RSPO2,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
CTNNB1 S33Y,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CTNNB1 S33Y,Viral,,CAGGS,,,,,,,,,,,,,,,,,,A dsRed control and CTNNB1 S33Y were cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP,"Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
HK2,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,HK2,,,,,,,,,,,,,,,,,,,,,"Human HK2 recombinant protein (0.5 μg; HXK0703, ATGEN) or total cell lysate",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
D4ER,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,D4ER,,,,,,,,,,,,,,,,,,,,,cells were transfected with the ER‐targeted D4ER Ca2+ probe,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
GCAMP6f,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,GCAMP6f,,,,,,,,,,,,,,,,,,,,,cells were transfected with a cDNA encoding mitochondrial and nuclear GCAMP6f,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
mit-Aeqmut,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,mit-Aeqmut,,,,,,,,,,,,,,,,,,,,,cells were transfected with a plasmid encoding low‐affinity mitochondrial matrix aequorin (mit‐Aeqmut),Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
GFP-PHD,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,GFP-PHD,,,,,,,,,,,,,,,,,,,,,cells were transfected with a plasmid encoding the GFP‐tagged pleckstrin homology (PH) domain of PLC‐δ1 (GFP‐PHD),Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
CRISPRv2,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPRv2,Viral,lentiCRISPRv2,,,,,,,,,,,,,,,,,,,TRAP1 and CyPD expression were knocked out using the lenti CRISPRv2 system,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
lentiCRISPRv2,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,lentiCRISPRv2,Plasmid,lentiCRISPRv2,,,,,,,,,,,,,,,,,,,"cloned into the transfer plasmid lentiCRISPRv2 (Addgene, https://www.addgene.org/52961/)",Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
Cyclophilin D,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cyclophilin D,Plasmid,pSUMO,,,,,,,,,,,,,,,,,,,The human CypD expression system was constructed by building the pSUMO-Cyclophilin D plasmid,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
mito-GFP1-9,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mito-GFP1-9,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,co-transfected with a combination of plasmids pcDNA3 mito-GFP1-9,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
TRAP1-GFP10,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TRAP1-GFP10,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3-TRAP1-GFP10,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
CyPD-GFP11,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CyPD-GFP11,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3CyPD-GFP11,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
ATP50-GFP11,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ATP50-GFP11,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3ATP50-GFP11,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
Agilent Human miRNA Microarray V2,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,False,0.50,Low,,,,,,,,,,,Agilent Human miRNA Microarray V2,,,,,,,,,,,,,,,,,,,,,Hundred nanogram of total RNA per sample was labelled and hybridised to the Agilent Human miRNA microarray V2,Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
miR-29c,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,miR-29c,,,,,,,,,,,,,,,,,,,,,"sNF96.2, was transfected in six-well plates using oligofectamine (Invitrogen) giving a final concentration of 100 nM of miRNA mimics (Dharmacon Inc.)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
Hematopoietic differentiation factors,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Hematopoietic differentiation factors,,,,,,,,,,,,,,,,,,,,,HPCs were generated using the STEMdiff hematopoietic kit (STEMCELL Technologies),Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
NF1 shRNA,genetic_reagents,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 shRNA,Viral,,,,,,,,,,,,,,,,,,,,"Lentiviral vectors expressing NF1 small hairpin (sh) RNA and shCtr were purchased from Sigma (CAT# TRCN000023878, TRCN0000039713, and SHC202)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
RABL6A shRNA,genetic_reagents,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RABL6A shRNA,Viral,pLKO.1,,,,,,,,,,,,,,,,,,,"Human RABL6A and RB1 shRNAs in the pLKO.1 lentiviral vector (Open Biosystems, Huntsville, AL, USA)",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
RB1 shRNA,genetic_reagents,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RB1 shRNA,Viral,pLKO.1,,,,,,,,,,,,,,,,,,,"Human RABL6A and RB1 shRNAs in the pLKO.1 lentiviral vector (Open Biosystems, Huntsville, AL, USA)",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
β-Galactosidase,genetic_reagents,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,β-Galactosidase,,,,,,,,,,,,,,,,,,,,,"stained using the Senescence β-Galactosidase Staining Kit (Cell Signaling Technology #9860, Danvers, MA, USA)",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Nf1-eGFP,genetic_reagents,PMID:34257279 | PMID:29670214,10.1038/s41467-021-24505-x | 10.1038/s41598-018-24310-5,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Restoring functional neurofibromin by protein transduction.,,0.9,Development,True,1.00,High,,,,,,,,,,,Nf1-eGFP,Plasmid,pUAST-attB,,,,,,,,,,,,,,,,,,,UAS-Nf1-eGFP transgenes were generated using an Nf1 mini-gene (full-length Nf1 cDNA corresponding to the RF isoform with addition of introns 9 and 10). | full-length human neurofibromin with C-terminal eGFP tag (synNF1eGFP),Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | 
Nf1 RNAi,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,Nf1 RNAi,Other,,,,,,,,,,,,,,,,,,,,The Nf1 RNAi line was obtained from the Vienna Drosophila RNAi Center (VDRC #109637),Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
rl Sem,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,rl Sem,,,,,,,,,,,,,,,,,,,,,ERK was activated via expression of ERK with the gain-of-function mutation ERK 56 Sem (UAS-rl Sem).,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
nSyb,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,nSyb,,,,,,,,,,,,,,,,,,,,,The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635),Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
R57C10,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,R57C10,,,,,,,,,,,,,,,,,,,,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
tsh-Gal4,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,tsh-Gal4,,,,,,,,,,,,,,,,,,,,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171), 69B (1774), tsh-Gal4 (3040)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Oct-TyrR-Gal4,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Oct-TyrR-Gal4,,,,,,,,,,,,,,,,,,,,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171), 69B (1774), tsh-Gal4 (3040), and Oct-TyrR-Gal4 (36494).",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
PCB-Gal4,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PCB-Gal4,,,,,,,,,,,,,,,,,,,,,PCB-Gal4 (fatbody-Gal4) was previously generated by Ronald Kühnlein,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
StemSep,genetic_reagents,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,StemSep,Other,,,,,,,,,,,,,,,,,,,,Lineage-marker-negative (Lin-) cells were purified through a 0.3-in StemSep negative selection column as per the manufacturer's instructions,"Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
WT1-AS,genetic_reagents,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,WT1-AS,Plasmid,pcDNA,,,,,,,,,,,,,,,,,,,"The human lncRNA WT1-AS were cloned into plasmid cloning DNA (pcDNA) vector | The WT1-AS sequence including the putative binding sites of miR-494-3p was subcloned and then inserted into the pmirGLO vector (Promega, Madison, Wisconsin)",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
psPAX,genetic_reagents,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,psPAX,Plasmid,,,,,,,,,,,,,,,,,,,,co-transfected with the packaging plasmids psPAX (Addgene #12260),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
pMD2.G,genetic_reagents,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pMD2.G,Plasmid,,,,,,,,,,,,,,,,,,,,"and pMD2.G (Addgene, #12259)",Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
UAS:eGFP-KRAS G12D,genetic_reagents,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,UAS:eGFP-KRAS G12D,Transposon,Tol2,UAS,,,,,,,,,,,,,,,,,,injected with Tol2(UAS:eGFP-KRAS G12D) plasmid,Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
NF1 siRNA,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 siRNA,Other,,,,,,,,,,,,,,,,,,,,"transfected with 4 siRNAs (FlexiTube, Qiagen, Hilden; Supplementary Table 2) designed for silencing the NF1 message",Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
Control siRNA,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Control siRNA,Other,,,,,,,,,,,,,,,,,,,,As a control the Allstar Negative Control siRNA (Qiagen) was used,Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
Lipofectamine RNAiMAX,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine RNAiMAX,Other,,,,,,,,,,,,,,,,,,,,using the Lipofectamine RNAiMAX transfection reagent (Life Technologies),Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
xGen UDI-UMI Adapters,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,xGen UDI-UMI Adapters,Other,,,,,,,,,,,,,,,,,,,,cfDNA sequencing libraries were constructed from 10 to 60 ng of isolated DNA using the KAPA HyperPrep kit (Roche) and xGen UDI-UMI Adapters (IDT),Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
TruSight Oncology 500,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSight Oncology 500,Other,,,,,,,,,,,,,,,,,,,,Tissue genomic profiling was performed by Clinical Laboratory Improvement Amendments–certified molecular laboratories using TruSight Oncology 500 (Illumina),Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
pBABE vectors,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pBABE vectors,Viral,pBABE,,,,,,,,,,,,,,,,,,,pBABE vectors were used for expression of constitutively active (CA: S217E/S221E) and dominant negative (DN: S217A) MEK1 and hyperactive RAS (G12D mutant),Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
luciferase,genetic_reagents,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,luciferase,Viral,lentivirus,,,,,,,,,,,,,,,,,,,GL261-luc cells were generated by infection of lentivirus carrying luciferase as described.,Publication title lacks NF-specific terms: Neutrophil depletion enhanced the
psPAX2,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,psPAX2,Plasmid,psPAX2,,,,,,,,,,,,,,,,,,,"Lentiviral transfer plasmid plus packaging plasmids psPAX2 (gift from Didier Trono, Addgene Plasmid #12260, RRID:Addgene_12260) and pCMV-VSV-G",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
VSV-G,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,VSV-G,Plasmid,pCMV-VSV-G,CMV,,,,,,,,,,,,,,,,,,"pCMV-VSV-G (gift from Bob Weinberg, Addgene Plasmid #8454, RRID:Addgene_8454) were cotransfected intro HEK-293T cells",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
SUZ12,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SUZ12,Plasmid,pLV-EF1α-IRES-Puro,EF1α,,,,,,,,,,,,,,,,,,"Human SUZ12 cDNA was cloned into pLV-EF1α-IRES-Puro (gift from Tobias Meyer, RRID:Addgene_85132)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
Tgfb3,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tgfb3,Other,,,,,,,,,,,,,,,,,,,,"Sequence-based reagent Tgfb3-MO Gene Tools, LLC Lissamine-tagged, tgfb3-targeting Morpholino",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
Tgfb1b,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tgfb1b,Other,,,,,,,,,,,,,,,,,,,,"Sequence-based reagent Tgfb1b-MO Gene Tools, LLC Lissamine-tagged, tgfb1b-targeting Morpholino",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
tgfb3-EGFP,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,tgfb3-EGFP,Plasmid,pCS2+,,,,,,,,,,,,,,,,,,,Recombinant DNA reagent pCS2+ tgfb3-EGFP This paper; Figure 3—figure supplement 1B Vector for generating RNA,Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
nCas9n-nanos3'UTR,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,nCas9n-nanos3'UTR,Plasmid,pCS2,,,,,,,,,,,,,,,,,,,"Recombinant DNA reagent pCS2-nCas9n-nanos3'UTR Addgene, Plasmid #62542",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
LNTH-1363S,genetic_reagents,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LNTH-1363S,Other,,,,,,,,,,,,,,,,,,,,"After administration of 179 MBq [68Ga]Ga-LNTH-1363S, (FAP-directed radiotracer; mass dose, 90 ug)",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
pCW57.1,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pCW57.1,Plasmid,pCW57.1,,,,,,,,,,,,,,,,,,,The plasmids pCW57.1 (Addgene plasmid 41393),Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
KRAS WT,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KRAS WT,Plasmid,pDONR223,,,,,,,,,,,,,,,,,,,pDONR223 KRAS WT (Addgene plasmid 81751),Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
KRAS G12D,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KRAS G12D,Plasmid,pDONR223,,,,,,,,,,,,,,,,,,,pDONR223 KRAS G12D (Addgene plasmid 81651),Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
IGT-T192V1 Plus panel,genetic_reagents,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,IGT-T192V1 Plus panel,Other,,,,,,,,,,,,,,,,,,,,ES was performed by standard procedures using the IGT-T192V1 Plus panel (Integrated DNA Technologies) to capture selected targets.,Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
pGEX 4T-1,genetic_reagents,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pGEX 4T-1,Plasmid,pGEX,,,,,,,,,,,,,,,,,,,"Human MCL-1-glutathione-S-transferase (GST) and BCL-XL-GST fusion proteins were cloned into the pGEX 4T-1 expression plasmid (available from Addgene, Watertown, MA, USA)",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
SpCas9,genetic_reagents,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SpCas9,Plasmid,,CMV,,,,,,,,,,,,,,,,,,"MCF7 cells (1 × 10 6 ) were transfected with 1 µg of a 12:1 DNA ratio of the pCMV-T7-(FZ) SpCas9-BPNLS(SV40)-3xFLAG-P2A-Puro-R plasmid (modified from RTW3027, Addgene #139987)",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
Mycoplasma detection primers,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Mycoplasma detection primers,,,,,,,,,,,,,,,,,,,,,"All cultures were routinely tested for mycoplasma contamination (LookOut Mycoplasma PCR detection kit, Sigma-Aldrich, St. Louis, MO, USA)",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Hsp90β,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Hsp90β,Plasmid,pBad,,,,,,,,,,,,,,,,,,,"the human Hsp90β sequence was optimized and cloned into a pBad/Myc-Hisx6 vector (Invitrogen, Thermo Fisher Scientific)",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
MPNST PDX-1,patient_derived_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,MPNST,CB-17 SCID,MPNST,,,,,,"MPNST PDX-1 tumors in CB-17 SCID mice (Taconic, RRID:IMSR_TAC:cb17sc) were enzymatically dissociated, followed by subcutaneous injection into flanks",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
NF1-associated MPNST-PDX,patient_derived_models,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NRG,MPNST,,,,,,We developed 13 NF1-associated MPNST-PDX and identified mutations,Vague PDX name — no specific model ID (e.g. PDX-1): NF1-associated MPNST-PDX
NF1-MPNST patient-derived xenografts,patient_derived_models,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NSG,MPNST,,,,,,we developed a collection of NF1-MPNST patient-derived xenografts (PDX). These PDX were compared with the primary tumors,Plural/generic PDX description — re-mine for specific model IDs: NF1-MPNST patient-derived xenografts
